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ABSTRACT 
With the introduction of aggressive adjuvant chemotherapy, the long-term 
survival rate of patients with osteosarcoma of the extremities has recently 
improved. As a consequence, it is now possible to evaluate some prognostic 
factors on a sufficiently large number of long-term survivors. Elevated levels 
of ALP are observed in the plasma of osteosarcoma patients. However, due to 
the nonspecificity of the alkaline phosphatase, the usefulness of the measurement 
of plasma ALP are decreased. After the introduction of Wheat germ-lectin 
precipitation method by Rosalki and Ying Foo in 1984, the method was widely 
used in many laboratory for determinating of the alkaline phosphatase isoenzyme. 
The present study was divided into 2 parts. The quantitative measurement 
and the qualitative analysis of bone specific alkaline phosphatase in plasma and 
tumour tissue extract. 
In the part of quantitative measurement, we contiuously monitor the level 
of bone specific alkaline phosphatase in the plasma of the oeteosarcoma patients, 
and find out that the BALP level can help the diagnosis of the disease of 
osteosarcoma. The effectiveness of the chemotherapy was also monitor by the 
measuring of the plasma ALP isoenzyme level, comparing with the clinical 
symptom and radiological sign. Thirdly, the result of the plasma ALP level of 
the osteosarcoma patients, obtained at the time of diagnosis, preoperational 
postoperational，and at the time of relapse was analysed the result proved that 
activity of plasma ALP at the time of diagnosis is related to the prognosis of 
the osteosarcoma patient. The higher the level of plasma bone specific ALP, the 
shorter the time of relapse. Moreover, level of bone specific ALP of the 
osteosarcoma tissue extract sampled during operation was measured. Result 
proved that the level of ALP isoenzyme measured in the tumor tissue extract is 
I 
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significantly higher than that of the normal bone tissue. However, there is no 
significantly different between the patient with and without the recurrent of 
osteosarcoma. 
In the part of qualitative analysis, plasma and tissue extract of the 
osteosarcoma patients was analysis. Isoelectric focusing technique was used 
with agarose gel as supporting media and immunological staining was used to 
detect the presence of the bands of different ALP isoenzymes. The result showed 
that the increase portion of the ALP isoenzyme of the plasma and tumor tissue 
extract of the osteosarcoma patients is mainly the bone specific Isoenzyme. 
However, no abnormal band was observed by the present IEF technique. 
f 





Introduction Alkaline Phosphatase 
1 1 ALKALINE PHOSPHATASE 
1.1.1 Alkaline Phospha ta se Isoenzyme 
The human alkaline phosphatase [orthophosphoric-monoester phospho-
hydrolase (alkaline optimum), E.C.3.1.3.1, ALP] comprise a spectrum of 
multiple molecular forms originating from various organs including liver, bone, 
kidney, testicular, small intestine and placenta during pregnancy. These various 
forms of ALP catalyze the hydrolysis of orthophosphate esters, inorganic 
pryophosphate and also exhibite transphosphorylation activity at optimal 
alkaline conditions (pH « 9 to 10) liberating the inorganic phosphate group and 
an alcohol (Fig. 1-1). Therefore, they constitute a system of isoenzymes 
(isozymes). 
orthophosphatase 
ROP + H20 » R O H + HOP 
pyrophosphatase 
PPi + H20 2Pj 
phosphotransferase 
ROP + R6H ROH + R6P 
Fig. 7-/ General reaction that alkaline Phosphatase catalise. 
The ALP isoenzymes differ from one another partly by genetic factors 
and by post-translational modifications. The placental, intestinal, testicular and 
the so-called tissue non-specific alkaline phosphatases (TNS-ALPs) 27,57 differ 
by their primary sequences of the polypeptide chain and therefore, they are the 
products from different genetic loci. The first three loci are found near the end 
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end of the short arm of chromosome l88,89. The TNS-ALPs, including the 
skeletal，hepatic and renal enzymes, differ in the degree of post-translational 
modification, glycosylation (Fig. 1-2). Strictly speaking, they can only be 
referred as isoforms. 
Gene Level Post-translational Modiification 
(Isoenzyme) (Isoforms) 
Plancental \ _Skeletal 
(Regan) 
ALPs Tissue Non-specific Hepatiic 
— Intestinal —Renal N Fetal (Kasahara) 
~ T e s t i c u l a r � _Othe r s e.g. Netrophil 
\ (Nagao) r 
Fig 1-2 Alkaline phosphatase isoenzymes. The blacketed isoform was inappropiate 
expression in cancer, and act as the tumor marker. 
Previous reports showed that the carbohydrates moiety of the ALP 
glycoproteins contains hexosamlne (e.g., N-acetylglucosamine), hexose (e.g., 
mannose, glucose, fucose) and sialic acid (N-acetylneuraminic acid) 25，27’31. 
Detail analysis of the primary structure of the enzyme found that the liver/bone/ 
kidney isoenzyme comprises 507 amino acids, the intestinal 509 and the placental 
and the testicular isoenzyme comprises 513 amino acids. 
Komoda and Sakagishi37’38 demonstrated that the carbohydrate side chains 
protect the enzyme against protease digestion. They also demonstrated that the 
sialic acid residue may also stabilize the native conformation of the active 
enzymes when subjected to heating and to pronase digestion39. They also 
demonstrated that the hexoamine of the ALP contain the sequence similar to 
"sialic acid-galactose-N-acetyl-glucosamine" with the penultimate galactose 
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1.1.2 The Properties of Alkaline Phosphatases 
The alkaline phosphatase isoenzymes exhibit different properties when 
subjected to various treatments. Due to the different net molecular charges and 
the sizes of the molecule, the alkaline phosphatase isoenzymes exhibit different 
electrophoretic mobilities. Moss in 1982 found that when the five isoenzymes, 
which were extracted from different human tissue, are subjected to starch gel 
electrophoresis，two zones are frequently observed, a more anodal main zone 
and a low mobility, high molecular weight minor zone, which reflect exactly the 
properties of the major zone. The presence of minor zone result from the 
formation of the aggregation of other proteins and lipids with the hydrophobic 
domains of the ALPs, which located in the plasma membrane of the cell，leading 
to a larger sizes of the molecules, thus retarding migration in the starch gel. 
Among the five isoenzymes, placental enzymes show allelic variation resulting 
in three bands (Fig. 1-3). The difference in mobilities may probably be due to 
the different contents of their carbohydrate residue, and particularly on the 
presence of the negatively charged sialic acid since the desialated forms have 
identical isoelectric point. 
Different properties are expected in the isoenzymes originating from 
distinct gene locus. It can be inferred from the very marked stability of the 
placental isoenzymes towards heat treatment at 65°C. The placental isoenzyme 
is completely stable at this temperature whereas the other isoenzymes, especially 
those TNS-isoenzyme arising from bone, kidney and liver, show different degree 
of inactivation by heat. The very different thermostability observed in the 
placental isoenzymes is thus thought to be due to the difference in the primary 
sequence of the enzyme. 
Such difference in the primary sequence leads to the fact that they are 
i 
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I g 国 = 
I 
一 一 一 一 — — 一 — 」 丨 
MinorZone — 
• H I 1 
(With higher • • • mSm m.w. than the 
Main Zone) Bone Liver Kidney Small intestine Placenta 
Fig. 1-3 Diagrammatic summary of differences in properties between multiple forms of 
human alkaline phosphatase. Some of these (e.g., placental vs. non-placental phosphatases) 
originate at the level of the structural gene; others are probable the result of 
post-translational modifications. The forms shown are based on those separated by 
starch-gel electrophoresis. (Moss, 1982) 
also antigenicallv different. It has been observed in the placental and the 
non-placental isoenzymes. The sharing of some antigenic determinants between 
the placental and the intestinal isoform results in the cross reactions of these 
two isoenzymes with the whole antisera 8 . 
The placental enzyme also differs from the non-placental enzymes by many 
catalytic properties as they show different relative rates of hydrolysis towards 
various orthophosphates and pyrophosphate substrates, and greater degree of 
inhibition by L-phenylalanine and lesser inhibition by L-homoarginine or 
levamisole “8，80 .On the other hand, the liver and bone isoforms come from the 
i 
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same genetic loci and therefore have same thermostability, antigenicity and 
catalytic properties. The different properties of the alkaline phosphatase 
isoenzymes are summarized in Table 1-1. 
Table 1-1 Qualitative Properties of ALP Isoenzymes 
Source Heat Stabiliity (65�C) Inhibtor Antigenity 
L-Phe L-Homo Levam 
Liver Liable R I J S 
Bone Liable R I 1 S 
Plancenta Stable | r r D 
Intestine Liable I R R D 
L-Phe: L-Phenylalanine R: Resistant S : Similarity 
L-Homo: L'Homoarginine I: Inhibited D: Distinct 
Levam: Levamisole 
1.1.3 Serum Alkaline Phospha tases 
Serum from normal, healthy subjects always contain at least two isoforms 
of ALP, the liver and the bone ALP as detectable by electrophoresis or 
selective-inactivation techniques. The presence of the alkaline phosphatases， 
or generally speaking, any enzymes, in the serum is a result of the synthesis and 
release of the enzymes into the circulation by the organs involved. Their levels 
in the serum reflect the balance between the rate of synthesis and release into 
serum during cell turnover and the rate of clearance from the circulation. 
Increased serum levels of enzymes result from the proliferation of cells, an 
increase in the rate of cell turnover, passive leakage from the damaged or dying 
cell, or reduction of the rate of clearance. The low levels may be due to reduced 
synthesis, or to congenital deficiency or the presence of inherited variants of 
relatively low biological activity 57. Turnover studies have shown that the 
> 
6 
Introduction Alkaline Phosphatase 
half-lives of the isoenzymes vary with a much lower value for the intestinal 
isoenzyme than that for the hepatic enzyme, of the order of 2 day, while the 
placental ALP has the longest half life of 7 day. It is possible that，as in many 
secretory glycoproteins, the degradation of the ALP isoenzymes is carried out 
by the reticuloendothelial route 19，26’56,80. 
1.1.3.1 Placental Alkaline Phosphatase 
Placental alkaline phosphatase, derived from syntrophoblasts, becomes 
detectable in serum of pregnant women in 16th to 20th weeks of gestation and 
increase progressively up to onset of labour. They disappear within 3 to 6 days 
of the delivery of the placenta. Complications of pregnancy such as hypertension, 
pre-eclampsia, eclampsia and in the cases of threatened abortion are always 
reflected in elevated serum level of placental ALP 34. High level of serum 
placental ALP were sometimes found in patients with cholestatic liver diseases17. 
The inability of the placental ALP to cross the placenta renders the amount of 
this enzyme in the serum of newborn infant undetectable 
1.1.3.2 Intestinal Alkaline Phosphatase 
The isoenzyme analysis of serum has shown that small amount of intestinal 
ALP can be found in about 25% of normal sera, most of which are more probable 
to the subjects of B- or O-blood group who are secretor-positive. This may be 
explained by the recent work 57 which has shown to that intestinal ALP is bound 
by the erythrocyte of the group A but a lesser degree by those of the group B or 
O. The low level of this isoenzyme in normal serum is accounted for by its 
clearance from the circulation at a significantly higher rate than the other 
isoenzymes 17. After each meal, this isoenzyme has been shown to increase in 
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serum intestinal ALP are observed in various diseases of the digestive tract, 
liver cirrhosis, intrahepatic cholestasis and those patients undergoing chronic 
hemodialysis 16，36,77,82. 
1.1.3.4 Skeletal Alkalne Phosphatase 
The bone and liver ALPs are invariably present in serum. The bone-specific 
alkaline phosphatase is synthesized and secreted into the serum by the bone 
forming cells of the skeletal organ - osteoblasts. The bone-specific ALP has 
long been considered as an index of osteoblastic activity. The normal serum 
level of bone-specific ALP is dependent on age at about 4 times higher in puberty 
than in adult. This physiological increase in puberty reflects the higher 
osteoblastic activity which is essential for adolescent growth spurt of bone. 
After the growth spurt, the serum level of bone-specific ALP drops to a low 
level, about 50 IU/L and shows a steady rise throughout the life. Pathologic 
increase of serum bone specific ALP are observed in various malignant tumours 
possessing osteoblastic activity such as osteogenic sarcoma and secondary 
deposits of carcinoma in bone, Paget's disease of bone, osteomalacia and rickets 
resulting from malnutrition, malabsorption or renal failure85. Increase in 
osteoblastic activity is also observed in bone fracture, thereby, increasing serum 
level of bone-specific alkaline phosphatase. (Fig. 1-4) 
1.1.3.5 Hepatic Alkaline Phosphatase 
As shown in Fig. 1-4, normal serum level of the hepatic ALP increases 
steadily throughout life. The hepatic ALP is found in high concentration in the 
hepatobiliary tract, therefore, the diseases of intra- or extrahepatic cholestasis 
resulting from, for instance, advance primary liver cancer, carcinoma of the 




Introduction Alkaline Phosphatase 
600 - 1 
= [ l l l H Bone phosphatase 
1 500-
^ Liver phosphatase 
产 
I 4 0 0 -
!S \ 
i 300 " ! 
c 200 - 1 I .... 
� _ i W _ _ _ # ® 
0 i i I i I — I — I — i ~ 
10 20 30 40 50 60 70 80 
Age (years) 
fig- “4 Changes in the relative activities of bone and liver alkaline Phosphatase in 
human serum with age . 
1.1.3.3 Renal Alkaline Phosphatase 
Renal alkaline phosphatase is present in particularly high concentration in 
renal tubules and is absent in serum in normal healthy subjects29. Renal diseases 
also rarely lead to serum renal isoform but it has been observed during rejection 
of the renal transplant. 
1.1.3.6 Miscellaneous Alkaline Phosphatase 
The sera from patients with hepatobiliary disease show minor phosphatase 
component, with relatively higher molecular mass, form a low mobility band in 
starch gel or polyacrylamide gel electrophoresis. While in non-sieving media 
t 
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such as cellulose acetate, this band, because of the higher molecular charge, 
migrates more rapidly towards the anode than the main liver band. The band 
has been termed the "fast liver，，or。％ liver" fraction S7. This kind of ALP has 
been shown to be the hepatic enzyme in nature associating with fragments of 
cell membrane from biliary tract cells or hepatocytes. It has been termed biliary 
alkaline phosphatase, releasing into the blood as a result of cell damage 15. The 
presence of the fast liver band is a valuable evidence of the disease of 
extrahepatic obstruction. 
Another kind of ALP is found in sera from many patients suffering from 
malignant diseases. The first of such cancer-related isoenzymes to be discovered, 
the Regan isoenzyme, is essentially identical to normal placental alkaline 
phosphatase，even reflecting that isoenzyme's allelic variation. The identification 
of another PLAP-like isoenzyme, the Nagao isoenzyme, is found in testis and 
thymus and some other tissue. The overall incidence of these two isoenzymes is 
about 5-15%, while the incidence as high as 60% may be found in germcell 
tumor57. Reports have demonstrated that the serum samples of some patients 
with hepatoma show a more anodal band than the main intestine ALP in gel 
media. This band is termed the Kasahara isoenzyme which has the catalytic 
properties typical of intestinal phosphatase. However, unlike adult intestinal 
phosphatase，the Kasahara isoenzyme has terminal silialic acid residue and has 
a more rapid anodal migration on electrophoresis. 
These cancer-derived isoenzymes may be indistinguishable from the normal 
placental ALP, which can be accounted for by depression of the placental 
isoenzyme gene by the malignant cells. However some differences between these 
cancer-related ALP and their normal analogues presumably arise by post-
translational modifications that may be specified to cancer cells. Altered patterns 
of glycosylation may exist in cancer cell. Therefore, these isoenzyme may 
i 
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sometimes be detected at pre-malignant conditions 59. The properties of the 
three cancer derived ALP variants, the Regan, Nagao and Kasahara isoenzymes, 
were summarized in the following table. 
Table 1-2 Three cancer-derived ALP variants that are presumed to originate from 
inappropriate expression of Alkaline Phosphatase-Determining genes 
Normal isoenzyme Tumour variant Characteristic properties 
Term-placental ALP Regan isoenzyme Heat-stable, reacts with anti-placental 
"PLAP" ALP antlsera, L-Phe sensitive, variable 
electrophoretic mobility as PALP 
Testicular ALP Nagao isoenzyme Heat-stable, differ with PALP or Regan 
"PLAP-like" isoenzyme with some monoclonal anti-
bodies, L-Phe sensitive 
Fetal-intestinal ALP Kasarahara Heat stable, react with anti-intestinal 
isoenzyme antisera，binds to Reactive Yellow 13, 
L-Phe & L-Leu sensitive, sialylated, 
rapid anodal electrophoretic mobility 
1.1.4 Problems in Discriminating the Skeletal and Hepatic Alkaline 
Phospha tase in Serum 
Elevated serum levels of ALP are observed in many disease status, as 
previously described. Therefore, identification of the ALP isoforms that 
contribute to the raised serum level is important in diagnosis of many diseases. 
Identification of the placental and intestinal isoenzymes from the TNSALPs is 
quite straight forwards by exploitation of their thermostability and their different 
catalytic properties towards various substrates (Table 1-1). However, the 
distinction between hepatic and skeletal isoforms is not easily achieved due to 
their similar antigenicity, thermostability and catalytic properties towards various 
substrates and inhibitors, probably as a result of the translation from the same 
f 
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genetic locus. The great majority of the requests for the isoform analysis also 
aims at distinguishing the bone and liver as alternative or coexisting sources of 
the elevated ALP activity in serum. 
1-1.5 Quantitative measure of the Bone-Specific Alkaline Phosphatase 
Wheat Germ Lectin Precipitation 
Rosalki and Foo in 1984 first introduced a method to quantify serum 
bone-specific ALP by the use of wheat germ lectin63. Lectins are highly specific, 
carbohydrate binding proteins of plant origin, the wheat germ lectin from 
Triticum vulgaris specifically binds to the N-acetylglucosamine residue and its 
derivatives, e.g., N，N，diacetylchitobiose3 9 of the carbohydrates side chains of 
many glycoproteins. After binding to the sugars, its large molecular weight 
leads to the precipitation of the large lectin-glycoproteins complex. Since ALP 
isoenzymes are N-acetylglucosamine-containing glycoproteins, they have been 
demonstrated to be capable of being bound by wheat germ lectin with the skeletal 
isoform being preferentially bound. The sugar composition of skeletal ALP has 
higher content of N-acetylglucosamine than the hepatic, intestinal or placental 
isoform. Therefore, when the other three isoforms coexisting with the skeletal 
isoform, the very strong binding between the skeletal ALP with the wheat germ 
lectin rendering the percentage binding between that of the hepatic intestinal 
and placental isoform insignificant. 
The method described by Rosalki and Foo63 involved a precipitation of 
the skeletal isoform with wheat germ lectin and reconstituted the precipitate 
for the skeletal ALP assay, together with the assay of total ALP in plasma sample, 
the hepatic isoform being calculated from the difference between the two values. 
The liver fraction, or the supernatant, comprises mainly the hepatic isoform 
and some small amount of intestine and placental ALP isoenzyme. However, > 
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the activity of the intestine and placental ALP isoenzyme is too low to 
significantly interfere the result. They also demonstrated that around a quarter 
of the high-molecular weight biliary ALP would be co-precipitated as the skeletal 
fraction. However, this could be avoided by the pretreatment of the sample 
with Triton X-100. The function of Triton X-100 surfactant is to solubilize the 
membrane fragment of the biliary ALP, thus converting them into the hepatic 
isoform. On the contrary, the pretreatment of Triton X-100 will not affect the 
differentiation between the bone and liver isoenzymes. 
In addition, Rosalki and Foo reported that the skeletal isoform precipitated 
was only 80% of the total skeletal isoform present. This has been disproved by 
W. Behr and J. Barnert6 by their demonstration of complete precipitation of 
ALP activity (98-99%) by using cord sera which are shown to contain only 
skeletal ALP activity. The partial precipitation of the skeletal isoform by Rosalki 
and Foo may be due to the batch variation of the wheat germ lectin they 
purchased, and the inaccuracy of the method of heat inactivation electrophoresis. 
Futhermore, skeletal and hepatic ALP of the butanol or aqouse extract in 
the bone tissue were less effectively differentiated by wheat-germ lectin. The 
isoenzyme isolated from liver and placenta and the one extracted from bone are 
all similarly bound by the wheat-germ lectin. Whereas hepatobiliary and placental 
ALP in plasma are obviously not precipitated. It may be presumably because of 
alteration in surface carbohydrate during extraction52, or possibly because 
membrane-localized glycosyl-transferases modify the enzyme molecule as it 
passes into the intravasal space46"48. However, the extract from the bone contain 
mainly the skeletal isoenzyme, the percentage of the liver and other portion in 
the bone extract is negligible, so we can presume that the activity of skeletal 
isoenzyme approximately equals the total ALP activity in the bone extract. 
> 
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1.1.6 Qualitative Detection of ALP isoenzymes——Electrophorisis 
Zone electrophoresis followed by staining for enzymatic activity, usually 
with a-naphthyl phosphate as substrate and with a diazonium salt to detect the 
liberation of a-naphthol, is the most useful single technique for the qualitative 
detection of multiform of the alkaline phosphatase. Electrophoresis in gel media 
such as the starch or polyacrylamide, or the seiving-gel media such as the 
cellulose acetste or agarose gel were used. However, the incomplete separation 
of the skeletal and hepatic isoforms makes the densitometric quantification of 
the enzymes difficult 52,73. Afterall, some simple selective inactivation method 
may leads to a more district seperation between these isoenzyme. The simple 
heat inactivation assay will give semi-quantitative estimates of the bone-specific 
ALP, in which a residue activity of less than 20% after heat treatment at 56°C 
for 10 minutes reflects the presence of skeletal isoform in a larger proportion83. 
The improved sequential heat inactivation method at 56°C will give quantitative 
estimates of the bone-specific ALP but it is too tedious to perform and the 
calculation involved is quite complicated; therefore, it is impractical for large 
scale, routine analysis of the samples in clinical laboratories 3. Rosalki and Foo62 
also described another method for the separation of the skeletal isoform from 
the non-skeletal isoforms, namely affinity electrophoresis, by presoaking the 
cellulose acetate membrane with buffer including wheat germ lectin before 
electrophoresis. This method had been demonstrated to separate the skeletal 
isoform from the hepatic isoform, which could not be resolved completely in 
conventional unmodified method. Moreover, the pretreatment of the sample 
serum with the neuraminidase64'69 was also proved to give a better seperation 
of the two isoenzyme. 
The introduction of Isoelectric Focusing technique (IEF) improve the 




in 1987 reported a reliable and reproducable IEF technique27, using 1mm thick 
agarose mixing with ampholytes of pH 3.5-9.5 as suporting media, using 
electrode of pH 3-10, performing IEF at 15W constant power for 35 minutes 
and using 1-naphthy phosphate and diazonium salt as substrate. They found 12 
sharp and clear bands of different ALP isoenzyme with pi 3.01 to 4.86. Some 
other authors27，74’90，used polyacrylamide gel as supporting media or 5-bromo-
4-chloro-3-indoxyl phosphate as substrate. The different supporting media, 
different substrate used and different resulting bands found was summerized in 
the followering table 1-3. 
Table 1-3 Different IEF criteria used by previous researchers and the results found. 
Author Gel film Substrate pH No. of Isoelectric points (pi) 
& Stainrange range bands 
Liver Bone Placent. Intest. 
Griffiths Agarose 1-naphthy I phosphate 3.5-9.5 12 3.65 4.21 4.65 4.86 
& Black gel with 4-aminodiphenyl-
1987 amine diazonium salt 
Blum- polyacryl- 1-naphthyl phosphate 3.0-9.0 7 4.3 4.5 3.6 4.9 
Stolnick amide gel monosodium salt and 
1983 Variamin Blue with 
copper sulfate 
Sinha polyacryl- 5-bromo-4-chloro- 3.5-6.0 10 4.9 5.09 4.73 
1986 amide gel 3-indoxyl phosphate 
i 
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Electrophoresis allows us to see each of the isoenzyme, and especially the 
unusual isoenzyme. For instance, P.K. Sinha74 in 1986 find out two distinct 
band with pi spetra of 4.95 and 5.90 in patients with Pagefs disease. This show 
the great potential of the use of qualitative analysis of the alkaline phosphatase 
as a tool to discover the unusal isoenzyme of the individual patient group, 
probabily to detect or diagnose the presence of malignant disease. 
On the other hands, extract of the tumour tissue has also been analysed by 
the method of electrophoresis. The number and intensity of ALP bands separated 
by electrophoresis depends on the difference in carbohydrates and siaic acid 
content and vary considerably according to the methods used for extraction 
from tissue 23,44，S2. Many methods for extraction have been reported by the 
previous authors and some of them are summerized in the following table. 
Table 1-4 Qualitative analysis of alkaline phosphatase isoenzyme in the tumour extract 
Author Buffer used Media for Method used Results 
extraction 
K. Masuhara borate buffer n-butanol Chromatography a band with m.w. 80000 which 
(1987) & electrophoresis similar to the bone ALP 
H.'J.M. Cleve Tris buffer n-butanol IEF 4 band of isoenzyme of ALP 
(1984) but unable to qualitate thebone 
& liver isoform by scanning 
A.M. Levine amino,2-methyl- distilled electrophoresis Osteosarcoma tissue with 
(1979) 1-propanol water and IEF activity = 2.02 umol/min/mg 
(202 U/gm) 
L. Kadlecova 0.1 M borate redistilled electrophoresis Thermostability and the pH 






The current international definitions of Osteosarcoma base on the presence 
of tumour osteoid or immature bone, is unsatisfactory. With the development 
of Immunohistochemical staining the osteosarcoma is divided into four types, 
the osteoblastic, chondroblastic, fibroblastic and telangiectatic types. They all 
revealed a significant degree of alkaline phosphatase activity 9>54-68'81'86. while 
the c h o n d r o s a r c o m a and the f ibrosarcoma can be separated from the 
chondroblastic and fibroblastic osteosarcoma by their absence of alkaline 
phosphatase staining. They are summarised in the following table. 
Table 1-5 Immunohistochemical Findings in Different Types of Osteosarcoma in 
Comparison with other Chondroid Tissues 
Osteosarcoma Chondrosarcoma fibrosarcoma 
Osteo. Chondro. Fibro. Telang. 
ALPase + + + + + + + + + - -
Osteo.; Osteoblastic type, Chondro.; Chondroblastic type, Fibro.; Fibroblastic type, Telang.; 
Telangiectatic type, +++，• markedly positive, ++，• moderately positive, +,• slightly positive, 
negative. 
1.2.2 Epidemiology and Statistics 
Next to plasma cell myeloma, osteogenic sarcoma is the most common 
primary malignant tumour of the bone 19，40 86. The estimate incidence of this 
tumour is 1.7 cases per million per year in United States 40, 1.1 cases per million 





populations Although it can occur in any age group, 50% of the cases occur 
in the second decade. Males are more frequently than females; the ratio of 
incidence is 1.6 to 1.0. The median presentation in females is two years earlier 
than males. This is probably related to the earlier growth spur in females 3S. 
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Fig. 1-4 Age and sex distribution in 1095 patients with osteosarcoma 
diagnosed in Memorial Sloan-Kettering Cancer Center 1921 through 1979. 
The appendicular skeleton is most frequently involved and approximately 
51% of the tumour occur about the knee. On the other hand, osteosarcoma 
more readily in the areas with the greatest number of active osteoblastic ceils 
such as the metaphases of the long bones I2'35-40,86. 
1.2.3 Clinical Presentation 
Usually the young patients gives a short history of increasing pain and 




that trauma brings the patients' 
attention to preexisting tumour. y ^ ^ j J 
A history of limping or limb ^ W ^ 
protection may be reported. A ： ^ ^ ^ 
firm fusiform eccentric swelling 1 1 ^ f n 
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large tumour. Fig. / -5 Skeletal distribution in 1095 
osteosarcoma patients diagnosed at Memorial 
Sloan-Kettering Cancer Center 1921 through 
1979. 
1.2.4 Radiographic finding 
Radiographically osteogenic sarcoma may be lytic or sclerotic base on the 
amount of the tumour bone production 40,72，*6. Classically，the tumour is situated 
in the metaphysis of the long bone, the characteristic radiographic changes 
included; 
1) Destruction of pre-existence of cortical or medullary bone, the sun-ray 
burst. 
2) Calcification and bone production. 
3) Periosteal reaction with new bone formation, the Codman's triangle. 
However, neither of these signs is pathogonomonic for malignancy. 
The distinctive radiographic patterns were found by von Ronnen 56. The 
most frequent was the mixed type, which demonstrated mixed patterns of bone 
formation and destruction, and accounts for 75%, On the other hands, the 
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purely sclerotic type was 14% and the purely lytic type was 11%. However, no 
significant difference in survival were noted among the various type. 
Computerized Tomography (CT) and Magnetic Resonance Image (MRI) 
are valuable methods of finding the osseous and soft-tissue extent of the tumour 
and determining their relationship to major neurovascular structures and adjacent 
jo in ts 72,86 Radionucl ide bone scanning with technetium 99m methylene 
diphosphonate (99mTcMDP) assists in the detection of osseous metastatic lesions. 
Angiography is excellent in detect of local reccurent soft-tissue disease. 
1.2.5 Staging of Musculoskeletal Neoplasms 
It has recently been adapted by the American Joint Committee Task Force 
on Bone Tumour and proposed by them to the International Union Against 
Cancer (IUAC) for international usage. It is based upon the histological grading 
(G), anatomy site (T), presence or absence of metastasis (M) 20. The system is 
summarized in the following table: 
Table 1-6 Stages of Musculoskeletal Lesions 
Stage Description Grade(G) Site(T) Metastasis(M) Lodwick 
Begnine 
1 latent G0 T0 M0 la 
2 active G0 T0 M0 lb 
3 aggressive G0 T02 M" Ic 
Malignant 
I* low grade without G1 T12 M0 II 
metastasis 
II* high grade without G2 T u M0 III 
metastasis 
III * low/high grade with G12 T12 M1 W-\W 
metastasis 




The system was trials by the Musculoskeletal Tumour Society and was 
shown to practical, reproducible and valuable in surgical planing7，21. However, 
the usefulness was still limited for assessing prognosis for either groups of lesions 
or individual cases 86. 
1.2.6 Treatment of os teosarcoma 
In the past, amputation of the limb was the only treatment available60'78. 
During that period, the five-year survival rate was at best 20% 51. Recently, 
advances in chemotherapy and orthopaedic surgical techniques have significantly 
change the outlook for patients with osteosarcoma 86. Limb salvage operation 
with allografts, prothesis or rotationplasty technique plus the utilization of pre-
operational and post-operational chemotherapy 32，50 can improve the survival 
rate to the best 93o/011,40,55,65,86 Even in Rizzoli，where the prognosis has been 
worse than the other countries, the five-year survivial rate was improved from 
10% to 45% 70. 
1.2.6.1.Chemotherapy in Prince of Wales Hospital 
Three protocol of adjuvant chemotherapy was used in the Oncology 
Department o fPWH. The usual regime is protocol A, (Table 1-7) which contains 
three drugs; 
1) High dose of methotrexate (MTX), which is the inhibitor of folic acid and 
therefore inhibit the synthesis of DNA and thymidine monophosphate. 
2) Adramycin (Adr) and 
3) Cisplatinum (Cis), which are the inhibitor of mitotic division. 
t 
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Table 厂7 ReSime A chemotherapy used in the Oncology Department ofPWH for the 
osteosarcoma patients 
P a t e Drugs used Monitor in each course 
W e e k 1 Cis + Adr CBP，LFT，LDH, CrCI, and 
W e e k 3 MTX X-ray of the tumour site 
Week 4 MTX 
Week 5 MTX CXR every month 
Week 6 MTX CT before operation 
Week 7 Cis + Adr 
Week 10 Operation 
Week 13 Cis + Adr 
Week 15 MTX 
Week 16 MTX 
Week 17 Cis + Adr 
Week 19 MTX 
Week 20 MTX 
After week 20, if favourable, repeat the cycle from week 13 to 20, While 
in unfavourable cases, change to other regimes. 
The oncologists suggested that 80% - 95% of patients presumably had 
already systemic metastasis at the time of original resection65, therefore, post-
operative chemotherapy can significantly improve the survival rate. On the other 
hand, the pre-operative chemotherapy can decrease the tumor size and improve 
the ability of limb salvage operation. 
i 
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1_3 PLASMA AND TISSUE ALKALINE PHOSPHATASE IN NORMAL 
AND NEOPLASTIC CONDITION 
1.3.1 Normal values of plasma alkaline phosphatase 
The determination of plasma alkaline phosphatase values can be studies 
by different assay methods. Moreover, assay plasma levels may be expressed in 
various units, using different substrates and at varies temperatures. Different 
methods and unit used were sumerized in the following table. 
Table 1-8 Normal plasma alkaline phosphatase values in adults and children (Units/dl 
at 37°C) 
Adults Children 
Methiod Range Average Range Average 
International Unit (IU) 31-82* 56.5 72-247* 159.5 
Bondansky 1.5-4 2.6 5-14 7.7 
King Amstrong 4-10 8.0 10-25 20.0 
The International Unit of enzyme is micromloes per minutes, and the corresponding 
activity concentration is in unit per liter. 
* The substrate and the IU values are expressed in mmol/P-Nitrophenyl phosphate/ 
min of ml serum at 37°C. 
After the introduction of Wheat germ-lectin percipitation method by 
Rosalki and Ying Foo in 1984，the method was widly used in many laboratory 
for determinating of the alkaline phosphatase isoenzyme. The table 1-5 sumerized 
the normal value of the alkaline phosphates isoenzyme by using the wheat germ-
lectin percipitation method. The unit used in the present experiment for the 
alkaline phosphatase and its isoenzyme is the International Unit (IU), and the 
upper limite of bone specific ALP for adult is 56 IU/L, for adolescence with 
age 12 to 16 yrs is 165 IU/L. 
t 
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Tabk “9 ^°rmal value of alkaline phosphatase isoenzyme determinedby wheats 
lectm percipitation method, using international unit (IU). 
A u t h o r 他 抑 叩 Mean \ Range (S.D.) of ALP Isoenzyme 
Total Bone Liver 
— 
Rosalki & Foo Adult (Male) 108 (22) 81 (22) 27(9 4) 
1 9 8 4 (Female) 89 (19) 57 (11) 33 (8.2) 
Werner Behr 6day-14yr 189-662 120-544 
1 9 8 6 (130.9) (135.9) 
Adult (Male) 50-137 (17.4) 27-96 (14.5) 
(Female) 53-155 (29.6) 32-102 (18.4) 
PWH main lab. 12 yrs to 16 yrs 74 - 235 36 • 165 
> 1 6 y r s 40 -136 2 3 - 56 
K s . Leung Adult (Male) 39.76 (16.68) 
1 9 9 2 (Female) 31.36 (12.41) 
PWH = Prince of Wales Hospital Maim Laboratory 
The previous study in our laboratory49 main component of isoenzyme in 
children is bone specific isoenzyme, it declines rapidly in aldolesence. While 
the liver portion of the alkaline phosphatase was stadily increase with age 
(Figure. 1-6 a,b) below. 
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1.3.2 Clinical use of elevated plasma & t issue alkaline phosphatase 
level in neoplastic conditions 
McKenna and associates pointed out the possible prognostic value of the 
serum alkaline phosphatase level 54. This and other studies firmly established 
that these values are helpful in determining prognosis. Postoperative, post-
chemotherapy follow-up should include alkaline phosphatase determination, 
since the elevation of ALP activity herald the presence of residual, reactivate, 
and spreading osteogenic sarcoma. In other words, it detect the recurrence or 
metastasis of the disease. Moreover，plasma alkaline phosphatase level can also 
be used to monitore the effectiveness of chemotherapy. 
1.3.2,1 Helping the Diagnosis of the Osteosarcoma 
In general, there is fairly good correspondence between the activity of 
alkaline phosphatese and the degree of the osteoblastic activity within the 
osteosarcoma. Ultrastructure localization found out that alkaline phosphatase 
was located over the plasma membrane and associated subplasmalemmal vesicle, 
and vacuoles of osteogenic sarcoma cell4,84. Abnomally high level of the plasma 
alkaline phosphatase in patients with osteosarcoma, Previous works of many 
authors reported that 40% to 80% of the patients with osteosarcoma has elevated 
level of alkaline phosphatase, during the time of diagnosis5，54，70,79’81. Morover, 
previous work of our laboratory49 reported that all of the 15 osteosarcoma 
patients had elevated plasma alkaline phosphatase level at the time of diagnosis. 
Alan M. Levine et al. in 1979 found out that the alkaline phosphatase level in 
the osteosarcoma tissue extract was very high, with mean value of 0.2 umol/ 
min/mg tissue (200 U/gm tissue), comparing with that of the normal cortical 
bone44. These showed that plasma and tissue alkaline phosphatase can help 
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L3.2.2 Monitoring the 0 f 
The reduction of elevated plasma alkaline phosphatase values following 
chemotherapy is a valuable guild to administration of therapy (Fig. 1-8). It 
corelated to the decrease of osteoblastic activity of the tumor, reduction of the 
tumor size, and improvement of the clinical presentation. The return of abnormal 
level signals the recrudescence of active disease, and the increase of doses of 
adminstration of the chemotherapy, if toxicity permits, should be undertaken 
forthwith67-79. 
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Figure 1-7 The effect of neoadjuvant chemotherapy on serum alkaline phosphatase values 
in a patient with proximal humeral osteogenic sarcoma. The decine of elevated values to 
normal levels (shaded zone) signifies the sarcoma is responding favorably to 
chemotheraphy. (From Dr. G. Rosen) 
1.3.2.3 Predicting the clinical course 
With the introduction of aggressive adjuvant chemotherapy, the long-term 
survival rate of patients with osteosarcoma of the extremities has recently 
improved from approximately 10-20% 14 45 75 to 40-70%5'10'66. As a consequence, 
it is now possible to evaluate some prognostic factors on a sufficiently large 
number of long-term survivors. 
26 
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Pretreatment evaluation 
The results concerning the prognosis significance of the pretreatment 
plasma alkaline phosphatase level have been contradictory in patients with 
osteosarcoma‘ Thorpe et ai.79 from the National Cancer Institute at Bethesada 
(NCI) conclude that pretreatment plasma ALP level could be a prognostic factor 
in osteosarcoma: the higher the ALP levels, the higher the rate of relapse. This 
result was supported by G. Bacci in Rizzoli5 , which a larger group of 163 
osteosarcoma patients. However, the result of UCLA1 8 reached the conclusion 
that there is no direct relation between the elevated plasma ALP level, tumour 
recurrence and prognosis. The result were summerized in the following table. 
Table 1-10 Relationship between the level of serum ALP preoperative and postoperative 
to the prognosis of osteosarcoma 
Authors Preoperative No. of Percentage Time to 
ALP Level patient of relapsed recurrent 
G.Bacci Normal 42 19 % 17.1 months 
(1987) Elevated 121 64 % 10.8 months 
W.P.Thorpe Normal 13 31 % 33+11 wks 
(1979) Elevated 17 71 % 19+3 wks 
P.E.Scranton Normal 22 46 % Not reported 
(1975) Elevated 16 81 % 
Authors Postoperative No. of Percentage Time to 
ALP Level patient of relapsed recurrent 
G.Bacci Normal 89 55 % 13.2 months 
(1987) Elevated 32 90 % 6.0 months 
W.P. Thorpe Normal Result are not significantly different 
(1979) Elevated 
P.E.Scranton Normal - Not reported -
(1975) Elevated - 100 % 
> 
* 27 
Introduction Relation between ALP & Osteosarcoma 
Postoperative evaluation and correlation with prognosis 
G - Bacci also point out that there is the existence of a correlation between 
the postoperative serum ALP levels and the prognosis. In patients with elevated 
serum ALP level at presentation but drop back to normal after surgical removal 
of the tumour, the rate of recurrent was lower than that of the patients who 
lacks of this response. However, due to the different methods of operative 
treatment, different scheme of chemotherapy and thefalse increase due to the 
Kuntscher rod or the autograft, the relationship of the postoperative serum 
ALP level was not so significant as that of the pretreatment serum ALP values. 
Table 1-10 on the previous page. 
On the other hand, Alan M. Levine44 reported that with the activity of the 
sarcoma tissue extract higher than 0.6 umol/min/mg tissue (600 U/gm tissue), 
therate of recurrent was significantly higher than that of the patient with lower 
activity of the tumor tissue extract. 
Analysis of serum ALP at the time of relapse 
The studies of many previous authors proved that the serum ALP activity 
raised to an abnormal level at the time of recurrent or metastasis53. Moreover, 
the raise of serum ALP preceded by several weeks the appearance of symptom 
and clinical sign, and before the detection of metastasis by x-ray. In the study 
of G. Bacci5 for example, 31 out of 52 patients who developed metastasis during 
the adjuvant chemotherapy, had an abnormally high level of serum ALP. While 
the rise of the serum ALP preceeding any x-ray demonstration by 4 to 12 
weeks, and preceeding any clinical sign by 8 to 16 weeks. Therefore, serum 
ALP was included in many institudes during the period of follow-up. 
M.W. J, Davie in 1991 gave a very typical case report on the use of serum 
alkaline phosphatase to monitor the period of follow-up of a 65-year-old woman 
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with Pagefs disease 丨 H e found 
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^ the treatment and progression of osteosarcoma. 
1.3.3 Qualitative measurement of ALP in plasma and tissue extract of 
osteosarcoma patient 
It has been noted that some sorts of tumour, such as the hepatoms, 
testicular seminoma or pulmonary carcinoma etc., has specific isoform of alkaline 
phosphatase which formed by the transglycosilation probably by the tumour 
cells. For instance，the Regan, Nagasa and Krada isoforms of ALP. Kensaka 
Masukara in 198752 purified the bone specific ALP from the human osteosarcoma 
tissue. The procedure including the chromatography and electrophoresis. The 
purified enzyme is a glycoprotein with molecular weight 3 7 of 80,000 and is 
characteristically inhited by modest heat (56° C, 30 min.) and L-homoarginine 
but not by L-phenylalanine. These properties was similar to that of the bone 
specific isoenzyme reported previously. 
Therefore qualitative analysis of the plasma or tumour tissue extract of 
the osteosarcoma patient is very important and holpfully it may give a specific 
band which can help diagnosis of this disease. 
9 r 
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1.4 AIM AND SCOPE OF THE PRESENT DISSERATION 
Increase level of serum alkaline phosphatase has long been referred to as 
having increased osteoblastic activities in bone. It appears to be the only 
laboratory test for diagnosing and monitering the disease of bone forming 
tumour, especially the osteosarcoma. In the present study, level of bone-specific 
isoenzyme of alkaline phosphatase, in plasma and extract of the tumour tissue, 
was measured to see whether it could act as a marker of the bone forming 
tumour. 
The present study was divided into 2 parts.The quantitative measurement 
and the quantitative analysis of bone specific alkaline phosphatase in plasma 
and tumour tissue extract. 
In the part of quantitative measurement, we contiuously monitor the level 
of bone specific alkaline phosphatase in the plasma of the oeteosarcoma patients, 
and find out whether the BALP level can help the diagnosis of the disease of 
osteosarcoma. The effectiveness of the chemotheraphy was also monitor by the 
measuring of the plasma ALP isoenzyme level, comparing with the clinical 
symptom and radiological sign. Thirdly, the result of the plasma ALP level of 
the osteosarcoma patients, obtainded at the time of diagnosis, preoperational 
postoperational, and at the time of relapse was analysed and see wether the 
activity is related to the prognosis of the osteosarcoma patient, the length of 
period of the recurrence of the diseased. Moreover, level of bone specific ALP 
of the osteosarcoma tissue extract sampled during operation was measured. 
Relation between the level of ALP isoenzyme measured in the tumor tissue 
extract and the prognosis of the osteosarcoma patient was also studied. 
In the part of qualitative analysis, plasma and tissue extract of the 
osteosarcoma patients was analysis. Isoelectric focusing technique was used 
t 
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which allows us to see each of the isoenzyme, and especially the unusual 
isoenzyme. This show the great potential of the use of the alkaline phosphatase 
as a tool to discover the unusal isoenzyme of the individual patient group, which 
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2-1 DIFERENT GROUPS OF PATIENTS 
I n t h e P e r i o d o f October 1991 to April 1993, 20 patients with the desease 
of osteosarcoma; 34 patients with benign bone tumour and 26 patients with 
malignant tumour that migrated to the skeletal system were recorded when they 
were admitted or refered to the Department of Orthopaedics and Traumatology, 
Prince of Wales Hospital. They were divided into 3 groups, namely the 
Osteosarcoma group, the Benign group and the Metastasis group respectively. 
The patients were monitor until the April 1994. The mean follow up time of 
Osteosarcoma group was 17.8 months, 27.6 months for the Benign group and 
18.8 months for the Metastasis group. The details of patients of the different 
group was summerized in the following table. 
Tabbe 2.1 Different groups of patients collected in P WH 
Patient group Diagnosis No. of cases Mean Period for Monitor 
Group 1 Osteosarcoma 20 17.8 months 
Group 2 Benign bone tumor 34 27.6 months 
Group 3 2nd Bone Metastasis 26 18.8 months 
2.1.1 Monitering the plasma bone specific ALP 
2.1.1.1 Osteosarcoma group 
At the time of admission, history of the patien, especially the time for 
developing the symptom, and physical examaination were recorded. Biochemical 
investigation included the blood routine, plasma calsium, phosphate, and alkaline 
phosphatase isoenzyme was also recorded. Radiological investigation include 
the CXR, XR of two dimension of the tumour, bone scan, MRI etc was used to 
excluded any metastasis of the disease. Diagnosis was confirmed only by the 
t 
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histopathological result obtained at the time of biopsy，or during operation. 
Plasma alkaline phosphatase isoenzyme was measured at the time of 
diagnosis, in each course of pre-operational and post-operational chemotherapy, 
the day before and after operational removal of tumour or amputation, and 
during every follow-up clinic. In the period offoilow-up, CXR was taken every 
3 months or at the time when clinical sign or symptome suggest recurrent of 
disease. 
2.1.1.2 Benign bone tumour group 
Similar to the osteosarcoma group, history, physical sign, biochemical and 
radiological investigation were recorded at the time of admision. Diagnosis was 
base on the histopathological result. Plasma alkaline phosphatase isoenzyme 
was measured at the time of diagnosis, and each time of follow-up clinics. 
2.1.1.3 Metastasis group 
Clinical history, physical sign, and investigation, including the alkaline 
phosphatase isoenzyme, were recorded during the time of referal from the 
Oncology Department, The diagnosis of primary malignant tumour and the result 
of bone metastasis was made only by the histopathological report. 
2.1.2 Collection of plasma samples preserve of tumor t issue 
Patients arm was placed in extend position. Cephalic vein or Median Cubital 
vein was located. Tunaquited the arm and sterilized the puncture site with alcohol 
swab (BRAND). Venepunture was performed and 5 ml venous blood was 
aspirated with a 10 ml sterile syringe (TERUMO). Unfastened the tunaquit and 
withdrawed the syringe. Removed the neddle and immediately transferred the 
> 
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blood into a 10 ml heparinized tube containing beads coated with ammonium 
heparine (SARSTEDT) and mixed the tube gently for about 30 times. Plasma 
sample was obtained by centrifugation at 1,000 xg for 10 minutes and aliquoted 
into 3 Eppendorfs and stored at -70°C. 
In the Excision and Allograft operation, the entire tumor was excised with 
clear margine. The tumor tissue was splitted into 2 half with electric saw or 
bone cutter. One half was send to the Pathological Department for histo-
pathological diagnosis while the second half was kept for biochemical assay. 
The halvested tumor tissue was washed twice gently with normal saline, each 
for 2 minutes, to ensure that all the blood on the surface of the tumor was 
cleaned out. Then, the tumor was cutted into 10 equal parts and wraped inside 
double plastic bag with lable of the location and stored at -70°C. 
i -.�^^HBWl I 
Photo 2-1 Osteosarcoma tissue halvested during the Excision and Allograft operation 
and splited into 2 half. One for histopathological diagnosis and the other for biochemical 
assay. 
.1 i 1 A 
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2 2 QUANTITATIVE ANALYSIS OF THE PLASMA AND TISSUE BONE 
SPECIFIC ALKALINE PHOSPHATASE 
The method described by Rosalki and Foo in 1984 was adopted for the 
assay of bone-specific ALP. The original method required two-step incubation 
with a pre-treatment ot Triton X-100 provided that serum sample demonstrated 
the presence of biliary ALP. The pre-incubation was time consuming and could 
compricate the calculation of bone-specific ALP activity. The original author 
subsequently modified their method in 1986, so that only one step incubation 
would be necessary for the precipitation of bone-specific ALP. The modified 
method was adopted in the assessment of bone-specific ALP in the plasma 
samples and tumour tissue extracts. 
2.2.1 Extraction of t issue ALP 
2.2.1.1. Reagent 
Borate Buffer (0.1 Mf pH 7.03) 
6.183g boric acid (H3B03 : MW 61.83) was dissolved in approximately 
950 ml distilled water (pH = 5.5). The acid was titrated to pH 7.03 with 0.2 
NaOH at 18°C - 20°C. The solution was diluted to 1 L with distilled water. 
2.2.1.2. Homogenization of the bone tissue 
The bone tissue that freezed at -70�C was brought to room temperature 
and washed with ice-cooled 0.1 M sodium borate buffer (pH 7.03). The bone 
tissue was crushed into small pieces with the bone cutter, then, homogenized 
with liquid nitrogen in stainless steel homogenizer (Photo 2-2) cooled at -70°C 
overnight before homogenization. The homogenates were transferred to a pre-
36 
Materials and Methods Quantitative Analysis 
weighted 1.5 ml Eppendorf tube. The wet weight of the sample was recorded. 
Then the Eppendorf tube was covered with parafilm paper on which some small 
h o l e s were pinned with a needle. The sample was subjected to lyophilization 
for 24 hours by lyophilizer (LABCONCO). After lyophilization, the dry weights 
of the sample was recorded. This sample was stored at -70°C or subjected to 
ALP extraction immediately. 
2.2.1.3. Extraction of ALP 
The sample was transferred to pre-weighed 12 mm x 75 mm opaque plastic 
tube and the dry weight of the sample transferred was recorded. To each sample， 
2 ml 0.1 M sodium borate buffer (pH 7.03) was added and the ALP was extracted 
with constant mixing by inversion mixer for 24 hours at 4°C. The mixture was 
then centrifuged at 3,500 x g for 20 minutes at 4°C (Beckman AccuSpin FR). 
One hundred folds aqueous solution of the supernatant was prepared and the 
diluted supernatant was taken for routine ALP assays. 
M 
Photo 2-2 Stainless steel homogenizer used to crush and homogenized the tumour tissue 
37 
Materials and Methods Quantitative Analysis 
2.2.2 Assay for Bone-specific ALP 
2.2.2.1. Reagents 
Wheat Germ Lectin / Triton X-100 Mixture 
Lectin of wheat germ from Triticum vulgaris was purchased from 
SIGMA & Triton X-100 from Scintran BDH. A solution containing 0.0275 g 
lectin and 0.22 g Triton X-100 in 5.5 ml distilled water. Complete dissolution 
was achieved by vortexing the solution at least 30 minutes. 
p-Nitrophenylphosphate Substrate Solution for Autoanalysor 
(AMP Buffer Solution, American Monitor Cooperation) 
2.2.2.2. Procedures 
The plasma sample or the bone tissue extract stored at -70°C was thawed 
& brought to room temperature by 370C water bath. Precipitation of bone-
specific ALP was achieved by mixing 50 jliL plasma sample or diluted bone 
tissue extract with equal volume of wheat germ lectin/Triton X-100 solution. 
The mixture was incubated at 37°C in shacking water bath for 30 minutes. After 
incubation, the mixture was centrifuged at 2,000 x g for 10 minutes. The 
supernatant was taken for the estimation of non-bone ALP activity. 
Alkaline phosphatase kinetic assays were assessed by the hydrolysis of 
/7-nitrophenylphosphate at alkaline medium performed by COBAS BIO 
autoanalysor (ROCHE Diagnostica) • The liberated /?-nitrophenylate shows 
maximum absorption at 405 nm. The rate of the increase in yellow color is 
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50 \xL sample was pipetted to the tube for COBAS BIO autoanalysor. 
Photo 2-2. After the reagent chamber was filled with /7-nitrophenylphosphate 
substrate solution and the cuvette ring was loaded, the machine was set to 
‘ SINGLE RUN，and with the Test Number set to "25". We can start to measure 
the value of each sample tube. The Test "25" was previously set for measurment 
of the alkaline phosphatase with the followering parameters : 
1. UNITS u/L 
2. CALCULATION FACTOR 2258 
3. STANDARD 1 CONC 0 
4. STANDARD 2 CONC 0 
5. STANDARD 3 CONC 0 
6. LITMIT o 
7. TEMPERATURE [DEG. C] 37.0 
8. TYPE OF ANALYSIS 2 
9. WAVELENGTH [NM] 405 
10. SAMPLE VOLUME [UL] 6 
11. DILUTENT VOLUME [NM] 50 
12. REAGENT VOLUME 250 
13. INCUBATION TIME [SEC] 0 
14. START REAGENT VOLUME [UL] 0 
15. TIME OF FIRST READING [SEC] 110 
16. TIME INTERVAL [SEC] 10 
17. NUMBER OF READINGS 15 
18. BLANKING MODE 1 
19. PRINT OUT MODE 1 
For each sample, pair assays were performed, one for the total ALP in 
plasma or diluted bone tissue extract, and the other for the non-bone ALP in 
the supernatant of that sample after treated with lectin solution. Bone-specific 
ALP activity was calculated from the difference between the two values, as 
shown below: 
Bone-specific ALP (U/L) = Total ALP (U/L) - 2 x Non-bone ALP (U/L) 
Control sera from human (Total ALP activity = 150.74 土 4.08 U/L) and 
rabbit serum (Total ALP activity = 104.51 土 2.40 U/L) were included in each 
run of 22 assays. 
% 
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2.3 QUALITATIVE MEASUREMENT OF ALP ISOENZYME 
(Analytical Electrofocusing in Carrier Ampholyte pH) 
2.3.1 Equipment required 
Instruments and accessories 
Multiphor 11 electrophoresis unit with MultiDrive XL 3 .5 kV power supply 
MultiTemp II thermostatic circulator (220 v) 




GelBond PGA film 
IEF electrode strips 
Consumable Reagents 
Ampholine，pH 3.5-5.0 
Ampholine, preblended, pH 3.5-9.5 
All the above apparatus manufactured by Pharmacia Biotechnology AB Uppsala, 
Sweden. 
2.2.2 Practical procedure 
2.3.3.1 Gel casting 
Reagents 
Agarose 0.25 mg 
Sorbital 2.50 mg 
Ampholyte with pH 3 .5-9.5 2.00 ml 
Milliqute distilled water 23.00 ml 
A r - ^ — — — " 
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Procedures 
1. Cut the GelBond PAG film in tho the size 10 cm x 13 cm. Pour about 2 
mL of 75% ethanol onto the hydrophilic side of the Gelbond film and rubbing 
with Kleenic paper, this reduce the adhersive force of the GelBond PAG film. 
2. Level the leveling plateform by mount the levelling feet by turning the gel 
casting table upside down and screwing one foot into each corner. Pour 0.4 ml 
of distilled water on it and this is used to adhere the GelBond PAG film firmly 
onto the plateform. 
3. Lay a GelBond PAGfilm over it with the hydrophilic side up. Preheat the 
film by blowing hot air from a electric hair dryer, which is clipped by a stand 10 
cm above, for about 5 minutes. 
4. Prepare the appropriate volume of gel solution (25 ml). 
Combine 0.25 gm agarose, 2.5 gm sorbital and 23 ml distilled water in an 
Erlenmeyer flask. Place the flask in a cold water bath and heated to boiling 
while st ir i l ing. When the agarose is disolved completely, decrease the 
temperature to 75°C. Add 2 ml of the Ampholine with pH 3.3 - 9.5 and mixed 
throughly. 
5. Pour the gel solution gently onto the GelBond PAG film. Tilting of the 
leveling plateform is allowed to spread the gel solution evently on the film. 
Check that there are no air bubbles in the gel and make sure the plateform is 
leveled. 
6. Wait for 2 minutes to allow the gel cool and forming a 1 mm thick agarose 
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2 ' 3 ' 3 * 2 Sample preparation and application 
1. Applied 3 卩Lthe plasma sample or the tissue extract or the molecular 
weight marker with a 10 ^iL pipette. The plasma sample was freshed, undialysed 
and undiluted. 
2. The sample should be applied along the axis of the elctrophoresing 
direction. And recorded down the lable of the different bands. 
2.3.3.3 Electrofocusing 
Reagent 
Electrode solutions (pH range 3.5-9.5) 
Anode 
0.025 M Aspartic acid - 0.33 g Aspartic acid (MW:132) 
0.025 M Glutamic acid - 0.37 g Glutamic acid (MW:146) 
dissolve in distilled water to a total volume of 100 mL. 
Cathode 
2.0 M Ethylenediamine - 13.2 mL Ethylenediamine (MW:60) 
I 
0.025 M Arginine - 0.44 g Arginine (MW:174) ； 
0.025 M Lysine - 0.40 g Lysine (MW: 164) 
make up to 100 mL with distilled water. Stir until clear. 
Procedures 
1. Set MultiTemp II thermostatic circulator to 10°C, and switch it on 15 
minutes before beginning the experiment. 
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3 . Apply the electrode strips wetted with the appropriateelectrode solutions. 
4. Apply the samples as discribed on the above section. 
Running conditions for 1mm thick agarose gel in pH range 3.5-9.5 
Voltage (V) 500 V [ MAX ] 
Current (mA) 50 [ MAX ] 
Power (W) 15 [MAX] 
Time (min) 10 Hr [MAX] 
2.3.3.4 Western blotting of the protein 
One of the major recent advances in the analysis of protein after 
polyacrylamide or agarose gel electrophoresis has been the development of 
techniques for the transfer of the seperated protein from the gel to a thin support 
matrix, most commonly a nitrocellulose membrane, to which they bind and 
immobilized. This transfer procedure is referred to as a blotting. Under idea置 
condition, over 90% of the protein can be transferee!. 
Reagent 
1) Transfer Buffer (pH8.3) 
Tris-Base 3.0275 g/L 
Glycine 14.4885 g/L 
Methanol (20%) 200 ml/L ( 
2) Assay Buffer (pH 7.2) 
Tris-HCl 7.88 g/L 
Sodium Chloride 8.775 g/L 
3) Blotting apperatus kit 
4) Absorber, the filter paper and paper towers. 
5) Hybon C membrane 
> 
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6) Plastic Warp sheet 
Procedures 
1. Set up the blotting apperatus as the figure 2-1 below. 
2. Marked the surface of the Hybon C membrane that contact to the agarose 
gel which containing the seperated protein. And mark the position of sample 
application. 
3. Allow blotting for 1 hour 
4. Wash twice the transferee! membrane with assay bufer, each 10 minutes. 
M w e i 9 h , 0 , , K G 
Paper absorber 
一 — — — •. Hybond C membrane 
^ h m mtmmm mmm^ M M 
. • • . • . . . • * IEF agarose gel 一 一 一 — 二 二 
� I ^ m m I !• • 
I J �.IXT:TTri • „ I » . . • • strip of filter paper 
| % v l v / ! � : . : . : • • • • - Transfer bridge 
• • • Assay beffer 
’ • Transfer container 
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2.3.3.5 Detection methnHg 
i) Coomassie Blue R 250 stain 
The use of Coomasie Blue R 250 stain is for the protein staining. Therefore， 
not only the alkaline phosphatase but also all the protein in the plasma or tissue 
extract was stained by this stain. Moreover, the molecular weight marker was 
also stained by this Coomasie Blue R 250 stain. 
Reagent 
1) Fixing solution 
350 mL Methanol 
130 g Trichloroacetic acid 
35 g Sulphosalicylic acid 
make up to 1 Liter with distilled water and stir until completely 
dissolved. 
2) Preserving solution 
50 mL Glycerol (87%) 
175 mL Ethanol (95%) 
50 mL Acetic acid 
make up to 500 mL with distilled water and mix thoroughly. 
3) Staining solution 
1.5 g Coomassie Blue R 250 
105 mL Ethanol (95%) 
30 mL Acetic acid 
make up to 300 mL with distilled water and stir. 
‘ — I 
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4) Destaining solution 
350 mL Ethanol (95%) 
100 mL Acetic acid 
make up to 1 Liter with distilled water and mix thoroughly. 
Procedure 
1. Immediately after focusing remove the electrode strips 
2. Place the gel in fixing solution (1) for 5 minutes. 
3. Place the gel in 100 mL destaining solution (4) for 5 minutes. 
4. Place the gel in staining solution (3) at room temperature for 5 minutes. 
5. Transfer the gel to destaining solution (4) for two 10 minute washes, or 
until the background is clear, 
6. Preserve the gel by leaving it in preserving solution (2) for 5 minutes. 
7. Dry the gel using a stream of hot air by a electric hair dryer, which is 
clipped 10 cm above. 
ii) Indoxy phosphate-formazan stain 
Reagent 
Staining solution together with the substrate of the alkaline phosphates 
0.1 M Tris Buffer solution 50 ml 
M g S 0 4 5 mM 
MTT [3-(4,5-dimethylthiazole-2)-2,5-
diphenyltetrazolium bromide] 100 |ng/ml 
Procedure 
1 • Put the transfered membrane into a tube container. Pour the substrate and 
staining into the container. The substrate should be freshly prepared. 
f 
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2. Incubate at 37°C for 16 hours. 
3. Under this condition, the reaction is carried out in the dark. Therefore, 
tin foil paper is used to warp the container tube during the whole process. 
4. Enzymatic activity of the alkaline phosphatse isoenzyme appears as the 
blue bands. 
5. The molecular weight of the specific band was calculated according to 
the position of the different positions of the molecular weight marker stained 
by the Coomassie Blue R 250 stain. 
iii) Imunological antibody-antigen stain 
Reagent 
1) 200 ml 2% skin milk 
2) First antibody 
Peroxidase conjugated anti-mouse IGG 1:1000 
3) Second antibody 
Peroxidase conjugated sheep-anti-mouse IGG 1:500 
4) ECL Detecting agent (Amersham Int. plc’ Amersham UK) 
Procedures 
1) Place the transferred membrane into 2 % skin milk for one hour. All the 
enzyme on the membrane was binded with the skin milk protein. 
2) Treat the membrane with first antibody for 5 minutes. Only the ALP 
isoenzyme will be released from the skin milk protein and bine to the first anti-
body, 
3) Wash with Assay buffer twice, each for 5 minutes. Then, add the second 
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4) Wash again with Assay buffer twice, each for 10 minutes. 
5) Add the detecting agent and let the reaction run for 1 minute. The product 
after the reaction is flurorescent. Take out the membrane and wrap it with a 
transpeerent plastic wrap. 
6) Put an X-ray film on the membrane inside a X-ray box. The exposing time 
for the plasma sample is 10 seconds, and 3 minutes for the sample of tissue 
extract. 
7) Develope the X-ray film, bands of the plasma and tissue ALP isoenzyme 
could be observed on the X-ray film. 
2.4 M ETHOD OF STATISTICAL ANALYSIS 
The statistical results were analyzed by SPSS for Window, Release 5.0 ( 
© SPSS Inc., 1989-1992.). Including the Mean and Standard deviation, 
Wilcoxon Matched-Pair Signed-Ranks Test, Oneway ANOVA and Duncan's 
Mutiple Ranged Test was used. 
Due to the fact that normal plasma ALP activity varies a lot with in different 
age group. We use Match- Paired Test to test the significance of the mean of 
the individual pair in each patients according to the different age group. 
Moreover, since the number of sample is so small that the Student's T-Test 
cannot be used. The Non-parametric Test is the test of choice. Therefore, in the 
present study, the Wilcoxon Matched-Pair Signed-Ranks Test is used. Oneway 
ANOVA is the test used to compare the significance of the mean of more than 
two groups, it showed the significant between the groups but the details of p 
value between each pair of means is proved by the Duncan's Mutiple Ranged 
Test. 
j 
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3.1 QUANTITATIVE MEASUREMENT OF PLASMA AND TISSUE BONE 
SPECIFIC ALKALINE PHOSPHATASE 
3.1.1 General Information of the patients monitoring 
In the period of October 1991 to April 1993，20 patients with osteo-
sarcoma; 34 patients with benign bone tumour and 26 patients with malignant 
tumour that metastased to the skeletal system were recorded when they were 
admitted or referred to the Department of Orthopaedics and Traumatology, 
Pr ince of Wales Hospital. They were divided into 3 groups, namely the 
Osteosarcoma group, the Benign group and the Metastasis group respectively. 
In the Group 1，the patients with osteosarcoma, we have 4 patients with 
the age equal 12 years, and 16 patients above 16 year of age. The average age 
is 20.25 year. The male patient is predominated with the male to female ratio 
16 : 4. Histologically, there are 16 cases of osteoblastic osteosarcoma, 3 cases 
of chondroblas t ic osteosarcoma and 1 case of telengietic osteosarcoma. 
Radiologically, the tumor was classified as osteosclerotic (8 cases) when 
radiodense neoplastic bone dominated, osteolytic (5 cases) when radiolucency 
predominated and mixed (7 cases) when they were equal portion of each 
radiographic aspect. Most of the patients received 4 courses of pre-operational 
and post-operational chemotherapy. One case (SC) developed acute hepatitis ！ 
A virus infection (HAV) and another case (PTM) refuse the pre-operational 
chemotherapy. Most of the patients under went Excision and Allograft operative 
treatment. 
In the period of follow-up, 11 patients had recurrence of the osteosarcoma. 
The first metastasis site were located in lung in 5 cases and 2 cases in spine, on 
the other hand, 4 cases developed local recurrence in the operative site. The 
average recurrent time was 40.36 weeks. The 9 other patients remain disease 
i 
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free after the operation, with the mean follow-up period of 102.11 weeks. 
Therefore，in the present study, the group 1 patients (osteosarcoma) were 
subdivided into 2 sub-groups, namely, the recurred osteosarcoma group (Group 
1R) and the non-recurred osteosarcoma group (Group IN). The general 
information of the group I patient was summarized in the following table. 
Table 1 General information of the osteosarcoma patient group. 
Group Name Ag» D«f Dx. “ Diagnosis | X-ray POC Operaion "PSC |2nd. Mat. 
Gp 1R AKM" 18/M 15-Jul-92 C-B-S L illius 一 L + S 4 ~ 17-Feb-93 (E) 2 ^ 3 - ^ ^ 9 3 
CLY 14/M “ 20-Jan-9f""" T-Ost. R pclvic S 10-Jun-92 (E) 0 9-Nov-92 ~ 
"KCY~ 10/M 2 9 - A u g - 9 ~ C-B-S L tibia S 4 3-Jan-92 4 _ 26-May-92— 
T w s " 13/M ‘ 20-NOV-92 Ost. R tibia L + S ~ 8-Mar-93 (E + A> 3 “ 15-Feb-93 
T m C ~ 32/M 21-Sep-92 C-B-S pelvic L — 2 9-Nov-92 (E + R) 4 “ 18-Jan-94 
PTM 14/M 18-Feb-93 | R tibial ost . L 0 ~ 26-Feb-93 4 “ 27>Apr-94 
"SKW 11/M 13-Sep-91 Ost. L femur S 2~~ 24-Nov-91 4 “ 30-Apr-94~ 
"~SC 24/M 23-Jun-92 Ost. R tibia S 0 15-Jul-92 (E + A + N) 0 ~ 13»Jul-93 
TYC 38/M一 24-Apr>92 Ost. L famur S 2 3-Jul-92 0 5-Sep-92 
TCY 18/F 11-Sep-91 Ost. R tibia L 4 27-May-91 (E + A) 4 ~ 13-Nov-92 
"WCK 12/M 11-Mar-92 Ost. R tibia S 1 7-Apr-92 """""" 4 5-Jan-93 
Gp 1N CHL | 15/M j 8-Sep-92 Ost. R femur L + S 4 23«Oct-92 <E + A) 4 
~ Y I 27/F 11-Sep-91 Ost. R tibia L + S 一4 12-Jan-92 (E + A) 4 
KSP ！ 18/F j 23-Sep-91 Ost. R humerus L I 4 l26-Mar-1992 (E4-A) 4 
LFH 39/M j 22-Oct-92 ！ Ost. R knee L | 4 j 12-Feb-93 (E + A> | 3 
LKH 14/M i 8-Sep-92 ； Ost. R humerus L + S i 4 | 5-Mar-93 {E + A) | 3 
LW 36/F j 2-Sep.-91 ！ Ost. L tibia L + S | 4 ！ 25-Jan-92 | 4 
MSK 20/M 1-Sep.-91 I Ost. L tibia S I 4 j 3-Apr-1992 <E+A) j 3 
TCC 20/M 1-Oct-92 ！ Ost. L tibia L + S | 4 丨 17-Jui-93 [ ？ 
TCW "T2/M 1 16-Dec-91 ‘ Ost. L pelvic S ； 4 ! 12-May-93 ！ 4 
C-B-S Condroblastic osteosarcoma POC : Preoperational chemotheraphy 
Ost. : Osteoblastic osteosarcoma PSC : Postoperational chemotheraphy 
T-Ost. : Telengietic osteosarcoma Meta. .Date of clinically detectd metastasis 
L+S : Radiological mixed tumor 
L : Radiological osteolytic tumor 
S ： Radiological osteosclerotic tumor 
y rrr 
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In the group 2’ the patients with the benign bone tumor, we have 34 patients 
aged from 23 year to 55 year with average 32.8 years. 23 of them had disease 
of Giant Cell Tumor, 5 developed Echondroma，3 cases of Osteoma and 3 cases 
of Chondroma. The mean follow-up time was 27.6 months. 
In the group 3, the patients with malignant tumour that migrated to the 
skeletal system, they were older patients, with the average 63.7 years of age. 
The primary tumor site was from breast in 9 cases，8 cases from lung, 4 cases 
f rom cervix and 3 cases from intestine. The mean follow-up period for this 
group of patients was 18.8 months. 
3.1.2 Pretreatment evaluation 
At the presentation, both the plasma total and bone specific ALP level 
was elevated in all the 20 osteosarcoma patient. The mean value of the total 
alkaline phosphatase TALP level was 343.90 IU/L and with S.D. 180.64 IU/L, 
while the mean value of the bone specific alkaline phosphatase B ALP in plasma 
was 302.65 IU/L with S.D. 180.19 IU/L. The mean value of the NBALP in 
plasma was 41.25 IU/L with S.D. 11.80 IU/L. When Wilicoxon Matched-Pairs 
Signed-Ranks Test was performed, both the plasma TALP and BALP level 
were significantly higher than the normal value, p< 0.001. However, the non-
bone portion of the alkaline phosphatase NBALP remained in the normal range. 
The mean value of the plasma TALP and BALP activity in the patients 
with begnine bone tumor, the group 2 patients, was 79.68 IU/L with S.D. 22.69 
IU/L, and 31.29 IU/L with S.D. 10.27 IU/L, respectively. When Wilicoxon 
Matched-Pairs Signed-Ranks Test was performed, both the plasma TALP and 
BALP level were NOT significantly higher than the normal value, p> 0.05. 
The mean value of the plasma TALP and BALP activity in the group 3, 
the patients with malignant tumour that migrated to the skeletal system, was 
i 
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114.58 IU/L with S.D. 172.42 IU/L, and 34.15 IU/L with S.D. 8.17 IU/L, 
respectively. When Wilicoxon Matched-Pairs Signed-Ranks Test was performed, 
both the plasma TALP and BALP level were NOT significantly higher than 
the normal value, p> 0.05. 
When comparison of the plasma BALP and TALP level between the group 
2 and group 3 patient was performed, the Wilicoxon Matched-Pairs Signed-
Ranks Test showed that there was no significantly difference between the two 
groups of patients. The p value of the plasma TALP between the 2 groups is 
0.545 while the p value of the plasma BALP between the 2 groups is 0.079. 
Although both the p value is larger than 0.05，the plasma BALP significance is 
still better than that of the plasma TALP. 
By using the Oneway ANOVA, it was shown that there was a significant 
difference of the plasma BALP level in the osteosarcoma patient group (group 
1) amongst the normal control, group of patients having begnine bone tumor 
(group 2)，and that of the group of patients with primary malignant tumor 
metastasis to the skeletal system (group 3). F (3，106) = 64.0544，P< 0.0001, 
The Duncan Multiple Range Test was applied to asses the groups that contributed 
to the overall significance. The results are outlined in table 3-2 below, where 
'X' was marked between the specific 2 groups that have the significant difference 
at the level p< 0.05. 
Table 3-2 Duncan test showing the plasma BALP level of the corresponding groups of 
patients having a significant difference, as indicated by 'X'. 
Mean Group of patients Group 1 Group 2 Group 3 Normal 
305.15 Group 1 (osteosarcoma) X X X 
34.2941 Group 2 (Begnine tumor) X 
34.1538 Group 3 (Bone metastasis) X 
56.0000 Normal BALP value X 
i 
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Results Quantitative measurement 
Moreover, in the group 1 patients, when the value of BALP was divided 
by that of the TALP, we found that the bone portion of the plasma alkaline 
phosphatase enzyme was above 85%, with mean value 85.36% S.D. 7.50, it 
was significantly higher than the that of the normal subjects with portion of 
BALP in plasma 40%, p< 0.001. On the other hand, the bone portion of the 
group 2 and group 3 was 39.39% with S.D. 5.91 and 32.33% with S.D. 10.07’ 
respectively. The percentage was similar to that of the normal subjects. The 
detail result was recorded in table 3-3. 
Table 3'3 Mean and S. D. of the plasma ALP isoenzyme and the percentage of the BALP 
m different groups of patients. 
Group 1 Group 2 Group 3 
TALP I BALP % TALP BALP I % TALP [ BALP j % 一 
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 1
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Results 
Quantitative measurement 
Futhermore, the high S.D. value of the TALP in the group 3 patients, 
172.42 IU/L which is even higher than that of the mean value. This showed that 
the plasma TALP measurement was not as good as that of the plasma BALP 
measurement. 
The mean value and S.D. of the three groups of patients were summarised 
in the following figure 3-1 and the details of the values was in the table 3-4. 
Fi^ure 3'J Mean and of the plasma ALP level in the three groups of patients. Group 
/ , the group of patients with osteosarcoma, group 2, The group of patients with begnine 
bone tumor and ^oup 3, the group of patients with primary malignant tumor metastasis 
t0 skeletal system. TALP is the total plasma alkaline phosphatase, BALP is the plasma 
bone sPecific alkaline phosphatase and the NBALP represent the plasma mm-bone portion 
alkaline phosphatase. 
* 
Plasma ALP level in Different Groups of Patients 
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Results Quantitative measurement 
3.1.3 Correlation between the pretreatment plasma ALP levels and 
prognosis in the osteosarcoma patient group 
The mean value and S.D. of the group 1 osteosarcoma patients were 
summarized in the fo l lowing figure 3-2，we subdivided the group into 2 
subgroups, the recurrent group (group 1R) and the nonrecurrent group (group 
1N)，while the details of the values was recorded in the table 3-5. 
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Figure 3-2 Mean and S. D of the plasma TALP and BALP level in the 2 subgroup IN and 
I R patients at the time of diagnosis. 
At the time of diagnosis，the mean value of the plasma TALP level in the 
group 1R (osteosarcoma patients with recurrent disease) was 425.73 IU/L, S.D. 
197.76 IU/L, while the mean value of the plasma BALP was 248.33 IU/L with 
S.D. 92.22 IU/L. When Wilicoxon Matched-Pairs Signed-Ranks Test was 
performed, both the plasma TALP and BALP level were significantly higher 
than the corresponding value of the group IN (osteosarcoma patients without 
recurrence), with Z value = -2.3102, 2-Tailed P = 0.0209 which means p< 0.05. 
However, the non-bone portion of the alkaline phosphatase (NBALP) has no 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Results Quantitative measurement 
3.1.4 Correlation between the preoperational, post-operational 
plasma ALP levels and the prognosis of osteosarcoma 
After 4 courses of preoperational chemotherapy and at the day before 
operation, the mean value of the plasma TALP level in the group 1R 
(osteosarcoma patients with recurrent disease) was 425.73 IU/L, S.D. 72.09 
IU/L，while the mean value of the plasma BALP was 182.64 IU/L with S.D. 
56.14 IU/L. On the other hand, the mean and S.D. of the plasma TALP and 
BALP of the group IN was 151.44 IU/L with S.D. 66.96 IU/L, and 105.78 IU/ 
L with S.D. 69.90 IU/L respectively. The value was summarized in the following 
Plasm，BALP level in Different Groups of Osteosarcoma Patients 
• MEAN • S .D. 
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Figure 3~3 Mean and S.D. of the plasma TALP and BALP level in group 1 patients at the 
time pre-operation and post operation. 
When Wilicoxon Matched-Pairs Signed-Ranks Test was performed, both 
the plasma TALP and BALP level of the group 1R were NOT significantly higher 
than the corresponding value of the group IN (osteosarcoma patients without 
recurrence). In TALP value, -1.7178, 2-丁ailed P = 0.0858 which means p> 
0.05, and BALP value was a little bit better than the TALP value with Z =-1.820 
and 2-Tailed P significant = 0.0687, which means still p> 0.05. 
/ [7T 
Results Quantitative measurement 
At the time of post-operation, the mean value of the plasma TALP level in 
the group 1R (osteosarcoma patients with recurrent disease) was 132.73 IU/L, 
S.D. 33.05 IU/L, while the mean value of the plasma BALP was 92.27 IU/L 
with S.D. 23.09 IU/L. On the other hand, the mean and S.D. of the plasma 
TALP and BALP of the group IN was 114.22 IU/L with S.D. 35.56 IU/L, and 
69.22 IU/L with S.D. 37.86 IU/L respectively. The value was summarised in 
the f igure 3-3，while the details of the individual results was recorded in table 
3-5. 
Although the mean value of the plasma TALP and BALP level in the 
patients of recurred osteosarcoma was higher than that of the non-recurred 
group，but again, when Wilicoxon Matched-Pairs Signed-Ranks Test was 
performed, both the plasma TALP and BALP level were NOT significantly 
higher than the corresponding value of the group IN (osteosarcoma patients 
without recurrence). In TALP value，Z value = -1.6803，2-Tailed P = 0.0926 
which means p> 0.05, and BALP value was a little bit better than the TALP 
value with Z = -1.7178, 2-Tailed P = 0.0858，which still p> 0.05. Moreover, the 
2-Tailed significant value of the post-operation was even worse than that of the 
pre-operational value, figure 3-4. 
2-Tailed P value of the plasma TALP and BALP level between the 
osteosarcoma patients with and without recurrence 
O.l T 
0.09 J m m m m ^ ^ ^ m 




figure 3-4 2-Tailed 尸 value of the preoperation and postope ration BALP and TALP level 
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Results Quantitative measurement 
3.1.5 Analysis of plasma ALP levels at the time of relapse in 
osteosarcoma patients 
At the time relapse, the mean value of the plasma TALP level in the group 
1R (osteosarcoma patients with recurrent disease) was 413.18 IU/L, S.D. 150.61 
IU/L, while the mean value of the plasma BALP was 373.64 IU/L with S.D. 
150.19 IU/L, While the mean and S.D. of the plasma TALP and BALP of the 
group IN at the time of follow-up clinic was 82.56 IU/L with S.D. 25.14 IU/L, 
and 41.44 IU/L with S.D. 20.14 IU/L respectively. The value was summarized 
in the following figure 3-5, while the details of the individual results was 
recorded in table 3-5. 
Mean and S.D. of plasma ALP isoenzyme in group 1 patients at 
the time of relapse 
600 r 
500 j 
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Figure 5-5 Mean and S.D. of the plasma TALP and BALP level in group 1R patients at 
the time of recurrent and in the group IN patients at the follow-up clinic. 
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R e s u l t s Quantitative measurement 
When Wilicoxon Matched-Pairs Signed-Ranks Test was performed, both 
the plasma TALP and BALP level were s ignificantly higher than the 
cor responding value of the group IN (osteosarcoma patients without 
recurrence). Both the plasma TALP and BALP level has Z = -2.6656, 2-Tailed 
P significance = 0.0077 which means p< 0.05. 
Moreover, when the value of the plasma BALP of the group 1R patients 
at the time of recurrent was compare with the value of the same patient at the 
time of post-operation, there was significant increase. With Z =-2.5471 and 
2-Tailed P significance = 0.0109 which means p< 0.05. 
On the contrary, the values of the plasma BALP of the osteosarcoma patient 
without relapse of the diseased (group IN), has significantly decrease with 
the value of the same patient at the time of post-operation. Z value = -2.9341 
and 2-Tailed P significance = 0.0033, which means p< 0.05. 
3.1.6 Usefulness of the plasma ALP levels for monitoring the 
effect iveness of chemotherapy 
In the present study, most patients response to the pre-operational and 
post-operational chemotherapy. We found that the improvement of clinical 
symptoms and radiologically decrease of tumor size, was well correlated to the 
decrease of plasma BALP level of the patients. After each course of 
chemotherapy, the plasma BALP level dropped. Moreover, after operation, the 
plasma BALP level also showed a small decrease. The results of the plasma 
BALP level in the patients was recorded in the figure 3-6 below. 
However, there were 4 patients that were not tolerate to the preoperational 
chemotherapy. One of which, SC, developed acute hepatitis A infection and in 
cases ofLMC and TYC, they had developed severe side effect including vomiting 
> 
6 2 
Results Quantitative measurement 
and febrile reaction and therefore stopped the chemotherapy. The plasma BALP 
level of these 3 patients with the retread of chemotherapy was increased, which 
is correlated to the increase of the tumor size with clinical unimprovement of 
the symptom The last patient, CLY, although have a significantly decrease of 
plasma BALP level pre-operationally, the fluctuation of the BALP level before 
each course of chemotherapy showed us that he is also not response to the 
chemotherapy. The monitoring results of the plasma BALP of the patients that 
were not tolerated to the chemotherapy was recorded in the figure 3-7 below. 
Moreover, at the time of post-operational chemotherapy, the increase of 
plasma BALP level was latter proved with pulmonary metastasis or local 
recurrent of the disease. The increase of plasma ALP level at most 3 weeks 
precede any clinical symptom and 4 weeks precede any radiological evidence 
of recurrence of the disease. 
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Figure 3-6 Results of the pre-operational and post-operational plasma BALP level in the 
osteosarcoma patients that response well to the chemotherapy. 
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Results Quantitative measurement 
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Figure 3-7 Results of the pre-ope rational and post-operational plasma BALP level in the 
osteosarcoma patients that were not tolerated to the chemotherapy. 
3.1.7 Correlation between the ALP levels in the tumor extract and 
the prognosis of the osteosarcoma 
At the time of Excision and Allograft Operation, both the excised tumor 
and the normal cortical bone tissue sampled from the illiac bone graft was used 
for biochemical analysis. The mean value of the tissue BALP level in the group 
1R was 115.78 IU/L, S.D. 74.17 IU/L, while the mean and S.D. of the tissue 
BALP of the normal cortical bone of the same patient was 1.59 IU/L with S.D. 
1.10 IU/L. On the other hand, the mean and S.D. of the tissue BALP of the 
t 
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R e s u l t s Quantitative measurement 
group IN and their normal control was 50.26 IU/L with S.D. 35.02 IU/L, and 
1.70 IU/L with S.D. 1.06 IU/L respectively. The value was summarized in the 
following figure 3-8，while the details of the individual results was recorded in 
table 3-6. 
Onao—fcoma Tinm Wormil Cortical Bon< 
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Table 3-6 Mean and S. D. of the BALP activity in the tumor tissue extract and the normal 
cortical bone tissue extract of the Osteosarcoma patients. 
When Wilicoxon Matched-Pairs Signed-Ranks Test was performed, both 
the tissue BALP level of the recurrent and nonrecurrent group were significantly 
higher than their normal control, with significance at the level p< 0.05. The Z 
value = -2.6656 2-Tailed P = 0.0077 in group of osteosarcoma patients without 
recurrence of the disease ( IN) and the significant P value was even a little bit 
better in the group of patients with recurrent osteosarcoma (1R) with Z value = 
-2.9341, 2-Tailed P = 0.0033. 
On the contrarily, there was no significant between the normal control of 
the two group 1R and IN, with Z value =-4-0.4201 and 2-Tailed P significance 
= 0 . 6 7 4 4 which means p> 0.05. 
i 
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R e s u l t s Quantitative measurement 
When we compare the BALP activity of the tumor extract of the two group 
1 R a n d 1 N ， w e f o u n d that the mean value of the recurrent group was higher 
than that of the nonrecurrent group, 89.22 IU/mg dry sample to 50.18 IU/mg 
dry sample. However, when Wilicoxon Matched-Pairs Signed-Ranks Test was 
performed, there was no significantly different between these 2 group at the 
level of p = 0.05. The Z value was-1.4809 with 2-Tailed P significance = 0.1386 
which was larger than the acceptable significant level of p> 0.05. 
Fi^re 3'8 Mean and S. D. of the BALP activity of the osteosarcoma tissue and the normal 
control cortical bone tissue of the same patient. 
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R e s u l t s Qualitative measurement 
3.2 QUALITATIVE ANALYSIS OF THE PLASMA AND TISSUE 
ALKALINE PHOSPHATASE LEVEL 
3.2.1 Comparison of the result of Isoelectric focusing of the plasma 
ALP of the os teosarcoma patients and the normal subjects 
The result of the separation of pathological and normal plasma on agarose 
gel obtained by the isoelectric focusing (IEF) electrophoresis technique was in 
the following photo 3-1. The first lane (lane 1) is the lane of molecular weight 
marker stained by the Coomasie Blue R250 staining, which is the staining for 
protein. The plasma from the venous blood of the normal subject (lane 2), the 
plasma of the venous blood of the recurrent osteosarcoma patients (lane 3) and 
that of the osteosarcoma patients without recurrent of disease (lane 4) were 
stained by the immunological antigen-antibody staining. 
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Photo 3-1 The result of the separation of pathological and normal plasma on agarose 
gel obtained by the isoelectric focusing (IEF) electrophoresis technique. Details of each 
lane and bands are discribed in the text above. 
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Results Qualitative measurement 
It is show that in the first lane, the molecular weight marker, 8 bands were 
obtained. This is correlated to the 8 component inside the molecular weight 
marker with the pi point of 2.8, 3.5, 3.75,4.35，5.20，5.85 and 6.55 respectively, 
the result of the IEF gel after Western Blotting process of the normal and 
pathological plasma was recorded on the following figure 3-9. On the contrary, 
in every lane of the lane 2 to lane 4, four bands could be found. The Bl， B2, B3 
and B4 are carrying the pi point of 3.60，4.30, 4.95 and 5.85 respectively from 
the anode to the cathode. 
Location of different pi point of the Molecular weight marker 
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Figure 3-9 The result of the IEF gel after Western Blotting process of the normal and 
pathological plasma. 
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On the other hand, the result of the IEF gel after Western Blotting process 
of the normal and pathological plasma was recorded in the photo 3-2 below. In 
this gel, which is stained by the Coomasie Blue R250 staining after 1 hour 
process of Western blotting. The lane I is the reference control of the plasma 
of the osteosarcoma patient which has not been transfer to the membrane while 
the lane 2 is the plasma of the same patient which has been transfer to the 
membrane after 1 hour Western blotting. It can be seen that almost all the protein 
in the plasma had been transferred to the membrane. The lane 3 and 4 this are 
the plasma of the patient with benign bone tumor and the normal subject 
respective. In the lane 3 and 4，it could hardly found any bands on the IEF gel. 
This proved that almost all the protein in the IEF gel was transferred to the 
cellulose membrane by the Western Blotting process. 
I f c ^ i T t i n 




R e s u l t s Qualitative measurement 
3_2.1 Result of Isoelectric focusing of the ALP isoenzymes in the 
t i ssue extract of the osteosarcoma and normal bone 
The photo 3-3 showed the IEF gel of the tissue extract of the osteosarcoma 
tumor and the normal cortical bone tissue of the same patient. The first lane 
(lane 1) is the lane of molecular weight marker stained by the Coomasie Blue 
R250 staining, which has been described before. The second lane (lane 2), was 
the cord blood which only contain the bone specific ALP isoenzyme. The lane 3 
contain the normal bone tissue extract, the lane 4 were obtained from the extract 
of the osteosarcoma tissue of the same patients and lastly the lane 5 is the same 
tissue extract sample of lane 4 but previous treated with wheat germ lectin 
incubation. The lane 2’ 3, 4 and 5 were stained by the immunological antigen-
antibody staining. It is show that in all the lane 2 to 5 only 2 bands, instead of 
the 4 bands found in the plasma sample, was obtained. 
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Photo 3-3 The result of the separation of tissue extract on agarose gel obtained by the 
isoelectric focusing (IEF) electrophoresis technique. Details of each lane and bands are 
discribed in the text above, 
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4.1 USE OF QUANTITATIVE MONITORING OF PLASMA ALP AND 
MEASURING TISSUE ALP IN OSTEOSARCOMA PATIENTS 
Alkaline phosphatase is thought to be involved either in the calcification 
of the bone matrix and in the protein synthesis activity associated with the bone 
matrix production.18'79. Culture osteosarcoma cell from human cell line 22，and 
animal cell line 24, have been shown to produce large amounts of this enzyme. 
In the osteosarcoma patients, the disease of abnormally high production of 
osteoid or immature bone, there is fairly good correspondence between the 
activity of plasma ALP and the degree of osteoblastic activity of the tumor. 
Many authors reported that 40% to 80% of the patients with osteosarcoma has 
abnormally elevated activity of plasma ALP 5'50'70'79'81. In the first part of the 
present experiment, we found that in all the 20 patients with osteosarcoma, the 
plasma ALP level was abnormally high. The mean level of plasma TALP is 343 .90 
IU/L and that of the plasma BALP is 302.65 IU/L, they are significantly higher 
than the normal value of plasma TALP, 136 IU/L and the normal value of plasma 
BALP level, 56 IU/L respectively, at the level of p<0.001. We also found that 
the plasma TALP and BALP level of the group of patients with osteosarcoma is 
significantly higher than that of the group of patients with benign bone tumor 
'and that of the group of patients with malignant tumor metastasis to the bone, 
at the significant level p< 0.05. Therefore, it is proved that the measuring of 
both plasma TALP and BALP level is a fairly useful investigation to help diagnose 
the disease of osteosarcoma. The measuring of plasma ALP is especially useful 
in the clinically untypical or non-characteristic borderline cases, such as some 
benign bone tumor, the chondroma, osteoma, the giant cell tumor, or the 
discovery of the skeletal metastatic site of some other malignant tumor. 
i 
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In the cases of malignant tumor metastasis to skeletal system, the present 
sUidy showed that the plasma BALP level was not significantly higher than that 
of the normal value at the level p equals 0.05. The result was support by the 
previous work of Dr. K.S. Leung in our laboratory49 including 38 patients with 
osteolytic skeletal metastasis of the malignant tumor. However, some previous 
authors61 found that the level of plasma ALP was elevated in the patients of 
skeletal deposit of the malignant tumor. The variation may be explained by the 
fact that what they measured was the plasma total ALP (TALP) instead of the 
bone specific isoenzyme of ALP (BALP) used in our study. In the present 
experiment, the plasma TALP level of the patients with skeletal metastasis of 
the malignant tumor (group 3 patients) had a very high variation, which reflected 
by the high S.D. value of 172.42 IU/L which is even high than the mean value 
of the plasma TALP level of 114.58 IU/L. The large variation is due to the 
cases of hepato-carcinoma which had a very high level of NBALP, actually the 
hepatic isoenzyme of the plasma ALP, while the bone specific isoenzyme (BALP) 
remain normal. On the contrary, the plasma BALP level had a more accurate 
and smaller S.D. value of 8.17 IU/L. Therefore, we suggest that plasma bone 
specific isoenzyme of the alkaline phosphatase (BALP) should be measured 
instead of the plasma total alkaline phosphatase (TALP) level. 
With the simple lectin precipitation method introduced by Rosalki and 
Foo, we can accurately measure the bone specific isoenzyme of the alkaline 
phosphatase (BALP). The present study found that in the plasma of the patients 
with osteosarcoma, the ratio of plasma BALP to TALP is above 85 % which is 
significantly higher than that of the normal subjects, 40 %, and that of the patients 
with benign bone tumor and skeletal metastasis of malignant tumor. This is 
another usefulness of measuring plasma BALP which specifically reflected the 
osteoblastic activity of the osteosarcoma disease. 
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As we discussed before, with the introduction of aggressive adjuvent 
chemotherapy, the long term survival rate of osteosarcoma patients has recently 
be improved. As a consequence, its now possible to evaluate the prognostic 
factor of the long term survivor. Among the prognostic factors previously 
analysed by other researchers, the sex and age of the patients, the length of the 
pre-diagnostic clinical symptoms, the tumor size, the tumor site, radiological 
signs or even the pathological cell type of the osteosarcoma are of uncertain 
value 4s,紙7o’86 S o a s i n t h e p r e s e n t study, the above factor contributed very 
small the prediction of the prognosis of the disease of osteosarcoma. In the 
present study, subdivided the group of osteosarcoma patient into 2 subgroups, 
the group with recurrent of disease during the period of monitoring (1R), and 
the group of patients remain nonrecurre of the disease (IN) during the period 
of monitoring. When we compare the pretreatment level of plasma ALP, both 
the level of TALP and BALP of the group of patients with recurrent disease of 
osteosarcoma (1R) is significantly higher than that of the nonrecurre group 
( IN) at the level of p<0.05 (2-Tailed P significance = 0.0209). The result was 
supported by the previous work of Thorpe et al.79 from the National Cancer 
Institute at Bethesada (NCI), they conclude that pretreatment plasma ALP level 
could be a prognostic factor in osteosarcoma: the higher the ALP levels, the 
higher the rate of relapse. G. Bacci in Rizzoli 5 , which a larger group of 163 
osteosarcoma patients also support our finding. Price in 1987 91 proved that 
with the increase of mitotic activity of the osteosarcoma cell, the rate of relapse 
was increase. As we discussed before, the increase of cell activity and the 
increase of the production of bone matrix need the presence of ALP. Therefore, 
the osteosarcoma with higher the osteoblastic activity, which reflected by the 
higher the level of plasma ALP, will have higher chance of relapse. 
i 
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Moreover, the hypothesis of micrometastasis theory61’87 presume that all 
the patients without any evidence of metastasis of the disease of osteosarcoma 
developed micrometastasis or invisible deposit of the tumor cell through the 
entire body. Therefore, with higher the level of plasma ALP, the more the 
spreading of the microscopic tumor cell, the shorter the period of relapse and 
the worse the prognosis. 
In the present study, the level of the plasma ALP isoenzyme of the patients 
at the period after 4 course of preoperational chemotherapy but before the 
surgical treatment (preoperational) was measured. Moreover, the result of the 
postoperative plasma ALP isoenzyme activity was also compared. We found 
that both the preoperational and postoperative plasma BALP and TALP of the 
group of patients with recurrent osteosarcoma (IR) had a higher mean level 
than that of the nonrecure group (IN). However, the Wilicoxon Matched-Pairs 
Signed-Ranks Test proved that there was no significant difference between the 
2 groups of patients at p=0.05 level. In addition, when we compare the 2-Tailed 
P significance of the two group, the p value of the preoperational plasma ALP 
level is better (smaller) than that of the postoperative plasma ALP level. The 
result was summarized in the following table 4-1. This may be explained by the 
increase of variational factors, such as the factors of the different methods of 
operative treatment, different scheme of chemotherapy and the false increase 
due to the Kuntscher rod or the autograft, therefore, the relationship of the 
pos topera t ive serum ALP level was not so s ignif icant as that of the 
preoperational plasma ALP values. With the more the variation factors, the 
worse the significant value of the plasma ALP activity. Besides, the 2-Tailed P 
significance of the plasma BALP level was better than that of the plasma TALP 
level, both at the time of preoperation and postoperaton. This further proved 
the advance of plasma BALP to the TALP in monitoring the disease of 
osteosarcoma. 
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Time Isoenzyme Mean Value 2-Tailed P value 
Recurre (1R) Nonrecure (1N) 
Diagnosis TALP 425.73 IU/L 248.33 IU/L 0.0209 
BALP 384.64 202.44 0.0209 
Preop. TALP 209.45 154.14 0.0858 
BALP 182.64 105.78 0.0687 
Postop. TALP 132.73 114.22 0.0926 
BALP 92.27 69.22 0.0858 
Relapse or TALP 413.18 82.56 0.0077 
follow-up BALP 373.64 41.44 0.0109 
Table 4-1 The 2-Tailed P Significance of the plasma BALP and TALP level of the 
osteosarcoma patients with (1R) and without recurrence (!N) of the disease, at the time of 
diagnosis, preoperational (Preop.), postoperational period (Postop.), and at the time of 
relapse or at the regular follow-up clinic. 
The studies of many previous authors proved that the serum ALP activity 
raised to an abnormal level at the time of recurrent or metastasis5，53. Moreover, 
the raise of serum ALP preceded by several weeks the appearance of symptom 
and clinical sign, and before the detection of metastasis by x-ray. In the present 
study, the plasma ALP level of the group of patients at the time of recurrence, 
is significantly higher than that of the group of patients without the evidence of 
recurrence at the time of follower-up clinic. Moreover, the level of the plasma 
ALP is significantly increased from that recorded at the time of postoperation 
of the same patients. In addition the increase of plasma ALP level precede the 
clinical evidence of the relapse of the disease by 3 weeks and precede any 
radiological evidence of recurrence. 
f 
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This proved that plasma ALP can be a good indicator and should be 
included in the monitoring of the osteosarcoma patients. Futhermore, measuring 
of plasma ALP is a more simple and less invasive investigation than the 
radiological investigation, or histopathological results which required the 
technique of open biopsy. 
As it was proved by the study of Bacci et al.5 that the lack of response of 
the level of plasma ALP after the operative treatment, 100% of the patients 
relapsed in a shorter period of time. We found that all the 20 patients has a 
significant decrease of plasma BALP level after the operative treatment. This 
showed that the Excision and Allograft operation of the osteosarcoma patients 
is a proper and effective treatment. Besides, in the present study that the patients 
who response to the chemotherapy, had a clinical improvement of the symptoms 
and the radiological evidence of decrease of tumor size showed corresponding 
decrease of plasma BALP level. While in the group of patient tolerate to the 
chemotherapy, with increase of tumor size and recurrence of the clinical 
symptoms, their plasma ALP level was increased. This proved that the level of 
plasma BALP is a good indicator reflecting the osteobalstic activity of the 
osteosarcoma, it can be used to show the effectiveness of the chemotherapy. 
With the increase of plasma BALP level during the period of chemotherapy, 
Oncologists should be alerted of the torlerance of the therapy, increase of drug 
doses or changing of the other regime or even go directly to the operational 
treatment should be consider. 
When the result of BALP level of the osteosarcoma tissue extract was 
analysed, the present study showed that it was significantly higher than that of 
the normal cortical bone tissue sampled from the same patient, at the significant 
level p< 0.005. Moreover, the tissue needed for the biochemical assay is as 
little as 50 mg, it might be possible to get the tissue even at the time of biopsy. 
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Therefore, the present study proved that measuring the BALP level in the tumor 
tissue might be a useful tool helping diagnosing the disease of osteosarcoma. 
The result was supported by previous work of Alan M. Levine44 that with the 
activity of the sarcoma tissue extract was significantly higher than the normal 
bone tissue. He also reported that with the activity of the sarcoma tissue extract 
higher than 0.6 umol/min/mg tissue (600 IU/gm tissue), the time for relapse of 
the osteosarcoma was shorter. However, in the present study, although we found 
that the mean level of BALP in the tumor extract of the patients with recurrence 
of the disease, 115.78 IU/gm dry tissue, is higher than that of the patients with 
nonrecurre disease, 50.18 IU/gm dry tissue, the Wilicoxon Matched-Pairs Rank 
Signed Test showed that there is no significant difference between the 2 groups 
of patients at the level p< 0.05. It may be explained by the fact that the different 
regime of the postoperational chemotherapy and the difference of the operative 
treatment affect the significance of the BALP activity of the tissue extract. 
Table 4-2 The 2-Tailed P Significance of the BALP and TALP level of the osteosarcoma 
tumor tissue extract of the patients with and without recurrence of the disease.. 
> 
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Moreover, when the result of the tumor tissue BALP level of the present 
study is compared with that of the previous work done by Alan M. Levine, the 
mean BALP level in the tumor extract of the present study was 87.63 IU/gm 
dry tissue which is lower than the mean level, 202 IU/mg dry tissue, Levine's 
report. The variation might be due to the different method used to detect the 
ALP activity of the tissue extract, Levin used electrophoresis and substrate 
method which was different to our lectin precipitate method. 
The ALP activity we measured in the tissue extract was the BALP level, 
and the NBALP portion of the tissue extract is very small and can be neglected. 
In the discussion of the latter section, the qualitative analysis of the plasma and 
tissue ALP activity, it was proved by the method of isoelectric focusing 
electrophoresis technique (IEF) that the bone tissue or the osteosarcoma tissue 
only contain band of the bone specific portion of the ALP. 
4.2 ISOELECTRIC FORCUSING AS A TECNIQUE FOR QUALITATIVE 
MEASUREMENT OF PLASMA AND TISSUE ALKALINE PHOSPHATASE 
Using IEF on agarose gel with a pH gradient from pH 3.0 to pH 10，we 
have routinely detact 4 distinguishable bands of ALP activity in the plasma of 
the healthy subjects and in the plasma of osteosarcoma patients. As any technique 
that detects multiple bands of enzyme activity, two essential questions must be 
answered: Do the bands represent true ALP activity? What is the cellular origin 
of the multiple bands in the normal or pathological subjects? 
The use of immunological antigen-antibody staining in the present study 
answere the first question affirmatively. The antisera was specifically bind to 
the ALP isoenzyme or isoform, therefore, no other enzyme or protien other 
than the ALP can be stained by the present method. The second question may 
be approached by studying the composit picture derived from the normal and 
i 
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pathological plasma and that of the molecular weight marker. The relative 
position of each band can be estimate through the known value of the molecular 
weight marker. The four observed band, Bl , B2, B3 and B4 in lane 2 to 4 of 
photo 3-1 are at the same distance from the anode. Therefore, the plasma of the 
normal subject and the plasma of the 2 osteosarcoma patients are consider of 
having the same composition of the type of isoenzymes. The pi point of the 
band B l , B2, B3 and B4 of the normal and patient plasma are 3.60, 4.30’ 4.95 
and 5.85 respectively. By comparing to the results found by the previous 
authors27,74’90，we proved the band Bl and B2, is the liver and bone isoenzyme 
respectively. Moreover, as discribed by the previous author, the cord blood 
contain only the bone specific ALP. The only one band found in the IFE gel of 
cord blood (lane2 of photo 3-3) carrying the pi point 4.30. This futher proved 
that the band 2, is the bone specific ALP isoenzyme. 
The intensity of the band 2 is obviously higher in the plasma of the patients 
with osteosarcoma, the lane 3 and 4 of the photo 3-1, than that of the band 2 in 
normal plasma (lane 2). This is agree with the quantitative measurement of the 
plasma ALP isoenzyme level in the first part of the present study. 
When the result of the tissue extract of the osteosarcoma tissue and the 
normal bone extract (photo 3-3) is studied, no band can be found in the normal 
bone tissue (lane 2) and only 2 bands can be obtained from the tumor tissue 
extract (lane 4). The invisible of any bands in the lane 2 showed that the activity 
of the normal bone tissue extract is too low to be detected by the present IEF 
electrophoresis technique. After calculation and comparing with the molecular 
weight marker, the band found in tumor tissue (lane 4) carry the pi point of 
4.15 in the first band (Bl) and pi point equals 4.30 in the second band (B2). 
The second band (B2) is at the same position as the only band found in the cord 
blood (lane 2) which is equals 4.30. This showed that the band 2 found in the 
i 
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tissue extract is the bone specific ALP isoenzyme, which is the same as that 
found in the plasma in the photo 3-1. The detect of the more anodal minor band 
( B l ) is agree with the previous work of Moss et a l 5 7 in 1982. The presence of 
minor zone result from the formation of the aggregation of other proteins and 
lipids with the hydrophobic domains of the ALPs, which located in the plasma 
membrane of the cell, leading to a larger sizes of the molecules, thus retarding 
migration in the starch gel. Moreover, after the treatment with wheat germ 
lectin (lane 5 of photo 3-3), the B2 band of the lane 5 is obviously reduced. 
This proved that the bone specific ALP isoenzyme of the tissue extract is 
inhibited by the treatment of wheat germ lectin. This is agree with the result of 
the quantitative measure of the bone specific ALP, by the Rosalki's wheat germ 
lectin percipitated method, in the first part of the present study. 
In the present study, agarose gel was used as the supporting media for 
isoelectric forcusing of the alkaline phosphatase isoenzyme of the plasma and 
tumor tissue extract. It was suggested by the prevous researchers that agraorse 
gel is better than the polyacrylamide gel that smaller cathode shift is found in 
the agarose gel. Besides, the larger pore size of the agarose gel allow more 
protein molecules to pass through, this is more fruitful when the unknown size 
of the protein is going to be detected. Sinha 74 and some author27，如 suggest that 
1-2-naphthyl phosphates as substrate, coupled to a diazolium salt was responsible 
for difused and blurred bands in conventional IEF, therefore, in the present 
study, indoxyl phosphatase-tetrazolium salt combination has been used. Four 
bands are observed in the plasma and two bands are observed in the bone tumor 
tissue extract. However, by the method used in this study, no abnormal extra-
band, the tumor related or tumor marker can be discovered either in the plasma 
or in the tissue extract of the sarcoma patient. Therefore, a more detail method, 








The present study concluded that the measurement of bone specific 
isoenzyme of the alkaline phosphatase (BALP) of the plasma and tumor tissue 
extract is a useful investigation for the diagnosis of osteosarcoma. Besides, the 
pretreatment level of the plasma BALP is a good predicting factor of the 
prognosis of the disease. Moreover, plasma BALP activity can also be used to 
show the effectiveness of the chemotherapy and can be used to detect the relapse 
of the osteosarcoma. Therefore, we suggest the routine measurement of plasma 
BALP level in every case of suspected osteosarcoma, and should be included in 
the follow-up clinic. In addition, the qualitative measurement of the plasma and 
tumor tissue of the osteosarcoma patient proved that the increased portion of 
the ALP isoenzyme is the bone specific isoenzyme, however, there is not any 
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